

AUTHOR INDEX FOR VOLUME 24

A

- Abell, Creed W. See *Denney, Fritz, Patel, and Widen*, 60
- Ahotupa, Markku, and Mäntylä, Eero. Adipose Tissue Content as a Modifier of the Tissue Distribution, Biological Effects, and Excretion of a Hexachlorobiphenyl in C57BL/6J and DBA/JBOMF Mice, 464
- Aktories, Klaus, Schultz, Günter, and Jakobs, Karl H. Somatostatin-Induced Stimulation of a High-Affinity GTPase in Membranes of S49 Lymphoma *cyc⁻* and H21a Variants, 183
- Alberts, Pēteris. See *Nordström, Westlind, Undén, and Bartfai*, 1
- Alexander, R. Wayne. See *Wright, Eckstein, and Gimbrone*, 213
- Alley, Michael C. See *Brimjoin and Mintz*, 513
- Ames, Matthew M. See *Woodson, Selassie, Hansch, and Weinshilboum*, 471
- Anderson, D.C.
 King, Steven C., and Parsons, Stanley M. Inhibition of [³H] Acetylcholine Active Transport by Tetraphenylborate and Other Anions, 55
 King, Steven C., and Parsons, Stanley M. Pharmacological Characterization of the Acetylcholine Transport System in Purified *Torpedo* Electric Organ Synaptic Vesicles, 48
- Anderson, Leojean. See *Schellenberg and Swanson*, 251

B

- Barrett, A. N., Roberts, G. C. K., Burgen, A. S. V., and Clore, G. M. *Ab Initio* Molecular Orbital Calculations of Electron Distribution in Tetramethylammonium Ion, 443
- Bartfai, Tamas. See *Nordström, Alberts, Westlind, and Undén*, 1
- Battaglia, George, Shannon, Michael, and Titeler, Milt. Initial Detection of [³H]Prazosin-Labeled α_1 -Receptors in the Porcine Pituitary Neurointermediate Lobe, 409
- Baudry, Michel
 Kramer, Kathryn, Fagni, Laurent, Recasens, Max, and Lynch, Gary. Classification and Properties of Acidic Amino Acid Receptors in Hippocampus. II. Biochemical Studies Using a Sodium Efflux Assay, 222
 Kramer, Kathryn, and Lynch, Gary. Classification and Properties of Acidic Amino Acid Receptors in Hippocampus. III. Supersensitivity during the Postnatal Period and following Denervation, 229
- Beck, William T., Cirtain, Margaret C., and Lefko, Janet L. Energy-Dependent Reduced Drug Binding as a Mechanism of *Vinca* Alkaloid Resistance in Human Leukemic Lymphoblasts, 485
- Beerman, Terry. See *Rauscher and Mueller*, 97
- Belt, Judith A. Heterogeneity of Nucleoside Transport in Mammalian Cells: Two Types of Transport Activity in L1210 and Other Cultured Neoplastic Cells, 479
- Birkett, Donald J. See *Wanwimolruk and Brooks*, 458
- Blount, John F., Fryer, R. Ian, Gilman, Norman W., and Todaro, Louis J. Quinazolines and 1,4-benzodiazepines. 92. Conformational Recognition of the Receptor by 1,4-Benzodiazepines, 425
- Bockaert, Joël. See *Sladeczek and Mauger*, 392
- Borowski, E. See *Cybulska, Ziminski, and Gary-Bobo*, 270
- Bouchard, Jacques, and Momparler, Richard L. Incorporation of 5-Aza-2'-Deoxycytidine-5'-triphosphate into DNA: Interactions with Mammalian DNA Polymerase α and DNA Methylase, 109
- Brimjoin, Stephen, Mintz, Keith P., and Alley, Michael C. Production and Characterization of Separate Monoclonal Antibodies to Human Acetylcholinesterase and Butyrylcholinesterase, 513
- Brooks, Peter M. See *Wanwimolruk and Birkett*, 458
- Brown, Joan Heller
 See *Dunlap*, 15
 See *Heller*, 351

- Brown, Susan L., and Brown, Joan Heller. Muscarinic Stimulation of Phosphatidylinositol Metabolism in Atria, 351
- Burgen, A. S. V. See *Barrett, Roberts, and Clore*, 443
- Bylund, David B. See *Forte and Zahler*, 42

C

- Camus, J. C. See *Waelbroeck, Taton, Delhaye, Chatelain, Pochet, Leclerc, De Smet, Robberecht, and Christophe*, 174
- Cantoni, Orazio
 and Costa, Max. Correlations of DNA Strand Breaks and Their Repair with Cell Survival following Acute Exposure to Mercury(II) and X-Rays, 84
 See *Evans, Patierno, Wang, and Costa*, 77
- Catto, Brian A. See *Tracy and Webster*, 291
- Chatelain, P.
 See *Robberecht, Delhaye, Taton, De Neef, Waelbroeck, De Smet, Leclerc, and Christophe*, 169
 See *Waelbroeck, Taton, Delhaye, Camus, Pochet, Leclerc, De Smet, Robberecht, and Christophe*, 174
- Chow, Thomas, and Zukin, Suzanne. Solubilization and Preliminary Characterization of μ and κ Opiate Receptor Subtypes from Rat Brain, 203
- Christophe, J.
 See *Robberecht, Delhaye, Taton, De Neef, Waelbroeck, De Smet, Leclerc, and Chatelain*, 169
 See *Waelbroeck, Taton, Delhaye, Chatelain, Camus, Pochet, Leclerc, De Smet, and Robberecht*, 174
- Cirtain, Margaret C. See *Beck and Lefko*, 485
- Clore, G. M. See *Barrett, Roberts, and Burgen*, 443
- Colombo, Ambrogio. See *Gambetta, Lanzi, and Zunino*, 336
- Conney, Allan H. See *Miller, Huang, and Jeffrey*, 137
- Costa, Max
 See *Cantoni*, 84
 See *Evans, Patierno, Wang, and Cantoni*, 77
- Costa, Erminio
 See *Onali, Eva, Olinas, and Schwartz*, 189
 See *Onali, Olinas, and Schwartz*, 380
- Croft, Jane E. See *Robertson, Serabjit-Singh, and Philpot*, 156
- Cybulska, B., Ziminski, T., Borowski, E., and Gary-Bobo, C. M. The Influence of Electric Charge of Aromatic Heptaene Macrolide Antibiotics on Their Activity on Biological and Lipidic Model Membranes, 270

D

- Delhaye, M.
 See *Robberecht, Taton, De Neef, Waelbroeck, De Smet, Leclerc, Chatelain, and Christophe*, 169
 See *Waelbroeck, Taton, Chatelain, Camus, Pochet, Leclerc, De Smet, Robberecht, and Christophe*, 174
- De Neef, P. See *Robberecht, Delhaye, Taton, Waelbroeck, De Smet, Leclerc, Chatelain, and Christophe*, 169
- Denney, Richard M., Fritz, Richard R., Patel, Nutan T., Widen, Steven G., and Abell, Creed W. Use of a Monoclonal Antibody for Comparative Studies of Monoamine Oxidase B in Mitochondrial Extracts of Human Brain and Peripheral Tissues, 60
- De Smet, J. M.
 See *Robberecht, Delhaye, Taton, De Neef, Waelbroeck, Leclerc, Chatelain, and Christophe*, 169
 See *Waelbroeck, Taton, Delhaye, Chatelain, Camus, Pochet, Leclerc, Robberecht, and Christophe*, 174
- Drewes, Lester R. See *Zelevnikar and Quist*, 163
- Dubé, Christopher E. See *Murray, Wilkinson, and Marcus*, 129

0026-895X/83/060533-04\$02.00/0

Copyright © 1983 by The American Society for Pharmacology and Experimental Therapeutics.

All rights of reproduction in any form reserved.

- Duch, David S., Lee, Ching-Lun Lee, Edelstein, Mark P., and Nichol, Charles A. Biosynthesis of Tetrahydrobiopterin in the Presence of Dihydrofolate Reductase Inhibitors, 103
- Dunlap, Janet, and Brown, Joan Heller. Heterogeneity of Binding Sites on Cardiac Muscarinic Receptors Induced by the Neuromuscular Blocking Agents Gallamine and Pancuronium, 15

E

- Eckstein, Laurie S. See Wright, Alexander, and Gimbrone, 213
- Edelstein, Mark P. See Duch, Lee, and Nichol, 103
- Erickson, Leonard C. See Tew, White, Wang, Schein, and Hartley-Asp, 324
- Eva, Carola. See Onali, Olinas, Schwartz, and Costa, 189
- Evans, R. Mark, Patierno, Steven R., Wang, De-Shin, Cantoni, Orazio, and Costa, Max. Growth Inhibition and Metallothionein Induction in Cadmium-Resistant Cells by Essential and Non-Essential Metals, 77
- Eyer, Peter, Lierheimer, Elisabeth, and Strosar, Mira. Site and Mechanism of Covalent Binding of 4-Dimethylaminophenol to Human Hemoglobin, and Its Implications to the Functional Properties, 282

F

- Fagni, Laurent. See Baudry, Kramer, Recasens, and Lynch, 222
- Fairhurst, Alan S. See Thayer, 6
- Fischer, Paul H., Murphy, David G., and Kawahara, Rodney. Preferential Inhibition of 5-Trifluoromethyl-2'-Deoxyuridine Phosphorylation by 5'-Amino-5'-Deoxythymidine in Uninfected versus Herpes Simplex Virus-Infected Cells, 90
- Flaim, Kathryn E., Jefferson, Leonard S., McGwire, Joan B., and Rannels, D. Eugene. Effect of Halothane on Synthesis and Secretion of Liver Proteins, 277
- Florio, Vincent A., and Ross, Elliott M. Regulation of the Catalytic Component of Adenylate Cyclase: Potentiative Interaction of Stimulatory Ligands and 2',5'-Dideoxyadenosine, 195
- Forte, Leonard R., Bylund, David B., and Zahler, Warren L. Forskolin Does Not Activate Sperm Adenylate Cyclase, 42
- Fraser, Claire M. See Lilly, Jung, Seeman, and Venter, 10
- Fritz, Richard R. See Denney, Patel, Widen, and Abell, 60
- Froimowitz, Mark, and Matthyse, Steven. Conformational Properties of Butaclamol and Isobutclamol: Regularities in the Structures of Semirigid Neuroleptics, 243
- Fryer, R. Ian. See Blount, Gilman, and Todaro, 425
- Fyfe, James A., McKee, Susan A., and Keller, Paul M. Thymidine-Thymidylate Kinases from Strains of Herpes Simplex Virus with Modified Drug Sensitivities to Acyclovir and (E)-5-(2-Bromovinyl)-2'-deoxyuridine, 316

G

- Gambetta, Romolo A., Colombo, Ambrogio, Lanzi, Cinzia, and Zunino, Franco. Purification and Partial Characterization of a Daunorubicin-Binding Protein from Rat Liver, 336
- Gans, Joseph H. See Mulcahy, 329
- Gary-Bobo, C. M. See Cybulska, Ziminski, and Borowski, 270
- Gilman, Norman W. See Blount, Fryer, and Todaro, 425
- Gimbrone, Michael A., Jr. See Wright, Alexander, and Eckstein, 213
- Glazer, Robert L.
and Hartman, Kathleen D. *In Vitro* Translational Activity of Messenger RNA following Treatment of Human Colon Carcinoma Cells with Sangivamycin, 509
- Hartman, Kathleen D., and Knode, Marian C. 9-Deazaadenosine: Cytocidal Activity and Effects on Nucleic Acids and Protein Synthesis in Human Colon Carcinoma Cells in Culture, 309
- Goldblum, Amiram. Structure-Activity Relationships of Cholinesterase Inhibitors. I. Quantum Mechanical Study of Affinities of Phenyl N-Methyl Carbamates, 436
- Goodman, M. See Rosenkranz, Hoffman, Jacobson, Verlander, Klevans, O'Donnell, and Melmon, 429

H

- Haga, Tatsuya. See Nukada and Ichiyama, 366, 374
- Hansch, Corwin. See Woodson, Ames, Selassie, and Weinshilbourn, 471
- Hartley-Asp, Beryl. See Tew, Erickson, White, Wang, and Schein, 324
- Hartman, Kathleen D.
See Glazer, 509
See Glazer and Knode, 309
- Henis, Yoav I., and Sokolovsky, Mordechai. Muscarinic Antagonists Induce Different Receptor Conformations in Rat Adenohypophysis, 357
- Herbette, L., Katz, A. M., and Sturtevant, J. M. Comparisons of the Interaction of Propranolol and Timolol with Model and Biological Membrane Systems, 259
- Hoffman, B. B. See Rosenkranz, Jacobson, Verlander, Klevans, O'Donnell, Goodman, and Melmon, 429
- Hom, D. S. See Law and Loh, 413
- Huang, Mou-Tuan. See Miller, Jeffrey, and Conney, 137

I

- Ichiyama, Arata. See Nukada and Haga, 366, 374
- Ishii, Kenji. See Kamataki, Maeda, Yamazoe, Matsuda, and Kato, 146

J

- Jacobs, Robert S.
See O'Brien and Wilson, 493
See White, 500
- Jacobson, K. A. See Rosenkranz, Hoffman, Verlander, Klevans, O'Donnell, Goodman, and Melmon, 429
- Jakobs, Karl H. See Aktories and Schultz, 183
- Jefferson, Leonard S. See Flaim, McGwire, and Rannels, 277
- Jeffrey, Alan M. See Miller, Huang, and Conney, 137
- Jerina, Donald M. See Vyas, van Bladeren, Thakker, Yagi, Sayer, and Levin, 115
- Jung, Chan Y. See Lilly, Fraser, Seeman, and Venter, 10

K

- Kador, Peter F., and Sharpless, Norman E. Pharmacophore Requirements of the Aldose Reductase Inhibitor Site, 521
- Kamataki, Tetsuya, Maeda, Kaori, Yamazoe, Yasushi, Matsuda, Naomi, Ishii, Kenji, and Kato, Ryuichi. A High-Spin Form of Cytochrome P-450 Highly Purified from Polychlorinated Biphenyl-Treated Rats: Catalytic Characterization and Immunochemical Quantitation in Liver Microsomes, 146
- Kato, Ryuichi. See Kamataki, Maeda, Yamazoe, Matsuda, and Ishii, 146
- Katz, A. M. See Herbette and Sturtevant, 259
- Kawahara, Rodney. See Fischer and Murphy, 90
- Kellar, Kenneth J. See Schwartz, 387
- Keller, Paul M. See Fyfe and McKee, 316
- King, Steven C. See Anderson and Parsons, 48, 55
- Klevans, L. See Rosenkranz, Hoffman, Jacobson, Verlander, O'Donnell, Goodman, and Melmon, 429
- Knode, Marian C. See Glazer and Hartman, 309
- Kouakou, Yao. See Meunier, Puget, and Moisan, 23
- Kramer, Kathryn. See Baudry, Fagni, Recasens, and Lynch, 222
See Baudry, Fagni, Recasens, and Lynch, 222
- Kuhar, Michael J. See Zarbin, Palacios, and Wamsley, 341

L

- Lanzi, Cinzia. See Gambetta, Colombo, and Zunino, 336
- Law, P. Y., Hom, D. S., and Loh, H. H. Opiate Receptor Down-Regulation and Desensitization in Neuroblastoma × Glioma NH108-15 Hybrid Cells Are Two Separate Cellular Adaptation Processes, 413
- Leclerc, J. L.
See Robberecht, Delhay, Taton, De Neef, Waelbroeck, De Smet,

- Chatelain, and Christophe*, 169
 See *Waelbroeck, Taton, Delhay, Chatelain, Camus, Pochet, De Smet, Robberecht, and Christophe*, 174
Lee, Ching-Lun Lee. See *Duch, Edelstein, and Nichol*, 103
Lefko, Janet L. See *Beck and Cirtain*, 485
Levin, Wayne. See *Vyas, van Bladeren, Thakker, Yagi, Sayer, and Jerina*, 115
Lierheimer, Elisabeth. See *Eyer and Strosar*, 282
Lilly, Leslie, Fraser, Claire M., Jung, Chan Y., Seeman, Philip, and Venter, J. Craig. Molecular Size of the Canine and Human Brain D₂ Dopamine Receptor as Determined by Radiation Inactivation, 10
Loh, H. H. See *Law and Hom*, 413
Lucier, George W. See *Thompson*, 69
Lynch, Gary
 See *Baudry and Kramer*, 229
 See *Baudry, Kramer, Fagni, and Recasens*, 222

M

- Maeda, Kaori**. See *Kamataki, Yamazoe, Matsuda, Ishii, and Kato*, 146
Makar, A. B., and Tephly, T. R. Effect of Nitrous Oxide and Methionine Treatments on Hepatic S-Adenosylmethionine and Methylation Reactions in the Rat, 124
Mäntylä, Eero. See *Ahotupa*, 464
Marcus, Craig. See *Murray, Wilkinson, and Dubé*, 129
Matsuda, Yasushi. See *Kamataki, Maeda, Yamazoe, Ishii, and Kato*, 146
Matthysse, Steven. See *Froimowitz*, 243
Mauger, Jean-Pierre. See *Sladeczek and Bockaert*, 392
McGwire, Joan B. See *Flaim, Jefferson, and Rannels*, 277
McKee, Susan A. See *Fyfe and Keller*, 316
Melmon, K. L. See *Rosenkranz, Hoffman, Jacobson, Verlander, Klevans, O'Donnell, and Goodman*, 429
Meunier, Jean-Claude, Kouakou, Yao, Puget, Alain, and Moisand, Christiane. Multiple Opiate Binding Sites in the Central Nervous System of the Rabbit: Large Predominance of a *Mu* Subtype in the Cerebellum and Characterization of a *Kappa* Subtype in the Thalamus, 23
Miller, Jerry R., Silver, Paul J., and Stull, James T. The Role of Myosin Light Chain Kinase Phosphorylation in *Beta*-Adrenergic Relaxation of Tracheal Smooth Muscle, 235
Miller, Mark Steven, Huang, Mou-Tuan, Jeffrey, Alan M., and Conney, Allan H. Betamethasone-Mediated Activation of Biphenyl 2-Hydroxylation in Rat Liver Microsomes: Studies on Possible Mechanisms, 137
Mintz, Keith P. See *Brimijoin and Alley*, 513
Moisand, Christiane. See *Meunier, Kouakou, and Puget*, 23
Molinoff, Perry B. See *Pittman*, 398
Momparker, Richard L. See *Bouchard*, 109
Mueller, Gail. See *Rauscher and Beerman*, 97
Mulcahy, Linda S., and Gans, Joseph H. The Fidelity of Mouse Liver Mitochondrial DNA Polymerase following Long-Term Administration of Carbon Tetrachloride, Diethylnitrosamine, or Phenobarbital, 329
Murphy, David G. See *Fischer and Kawahara*, 90
Murray, Michael, Wilkinson, Christopher F., Marcus, Craig, and Dubé, Christopher E. Structure-Activity Relationships in the Interactions of Alkoxyethylenedioxybenzene Derivatives with Rat Hepatic Microsomal Mixed-Function Oxidases *in Vivo*, 129

N

- Nichol, Charles A.** See *Duch, Lee, and Edelstein*, 103
Nordström, Öte, Alberts, Pēteris, Westlind, Anita, Undén, Anders, and Bartfai, Tamas. Presynaptic Antagonist-Postsynaptic Agonist at Muscarinic Cholinergic Synapses: *N*-Methyl-*N*-(1-methyl-4-pyrrolidino-2-butynyl)acetamide, 1
Nukada, Toshihide
Haga, Tatsuya, and Ichiyama, Arata. Muscarinic Receptors in

Porcine Caudate Nucleus. I. Enhancement by Nickel and Other Cations of [³H]*cis*-Methyldioxolane Binding to Guanyl Nucleotide-Sensitive Sites, 366

Haga, Tatsuya, and Ichiyama, Arata. Muscarinic Receptors in Porcine Caudate Nucleus. II. Different Effects of *N*-Ethylmaleimide on [³H]*cis*-Methyldioxolane Binding to Heat-Labile (Guanyl Nucleotide-Sensitive) Sites and Heat-Stable (Guanyl Nucleotide-Insensitive) Sites, 374

O

- O'Brien, E. Timothy, Jacobs, Robert S., and Wilson, Leslie**. Inhibition of Bovine Brain Microtubule Assembly *in Vitro* by Stypoldione, 493
O'Donnell, M. See *Rosenkranz, Hoffman, Jacobson, Verlander, Klevans, Goodman, and Melmon*, 429
Olianas, Maria C.
 See *Onali, Eva, Schwartz, and Costa*, 189
 See *Onali, Schwartz, and Costa*, 380
Onali, Pierluigi
Eva, Carola, Olianas, Maria C., Schwartz, Joan P., and Costa, Erminio. In GH₃ Pituitary Cells, Acetylcholine and Vasoactive Intestinal Peptide Antagonistically Modulate Adenylate Cyclase, Cyclic AMP Content, and Prolactin Secretion, 189
Olianas, Maria C., Schwartz, Joan P., and Costa, Erminio. Involvement of a High-Affinity GTPase in the Inhibitory Coupling of Striatal Muscarinic Receptors to Adenylate Cyclase, 380

P

- Palacios, Jose M.** See *Zarbin, Wamsley, and Kuhar*, 341
Palatini, P. The Interaction between Full and Partial Inhibitors Acting on a Single Enzyme: A Theoretical Analysis, 30
Parsons, Stanley M. See *Anderson and King*, 48, 55
Patel, Nutan T. See *Denney, Fritz, Widen, and Abell*, 60
Patierno, Steven R. See *Evans, Wang, Cantoni, and Costa*, 77
Philpot, Richard M. See *Robertson, Serabjit-Singh, and Croft*, 156
Pittman, Randall N., and Molinoff, Perry B. Interactions of Full and Partial Agonists with *Beta*-Adrenergic Receptors on Intact L6 Muscle Cells, 398
Pochet, R. See *Waelbroeck, Taton, Delhay, Chatelain, Camus, Leclerc, De Smet, Robberecht, and Christophe*, 174
Puget, Alain. See *Meunier, Kouakou, and Moisand*, 23

Q

- Quist, Eugene E.** See *Zelevnikar and Drewes*, 163

R

- Rannels, D. Eugene**. See *Flaim, Jefferson, and McGwire*, 277
Rauscher, Frank, III, Mueller, Gail, and Beerman, Terry. The Effects of the Antitumor Protein Auromomycin on HeLa S₃ Nuclei: Release of Soluble Chromatin, 97
Recasens, Max. See *Baudry, Kramer, Fagni, and Lynch*, 222
Robberecht, P.
Delhay, M., Taton, G., De Neef, P., Waelbroeck, M., De Smet, J. M., Leclerc, J. L., Chatelain, P., and Christophe, J. The Human Heart *Beta*-Adrenergic Receptors. I. Heterogeneity of the Binding Sites: Presence of 50% *Beta*₁- and 50% *Beta*₂-Adrenergic Receptors, 169
 See *Waelbroeck, Taton, Delhay, Chatelain, Camus, Pochet, Leclerc, De Smet, and Christophe*, 174
Roberts, G. C. K. See *Barrett, Burgen, and Clore*, 443
Robertson, Iain G. C., Serabjit-Singh, Cosette, Croft, Jane E., and Philpot, Richard M. The Relationship between Increases in the Hepatic Content of Cytochrome P-450, Form 5, and in the Metabolism of Aromatic Amines to Mutagenic Products following Treatment of Rabbits with Phenobarbital, 156
Rosenkranz, R. P., Hoffman, B. B., Jacobson, K. A., Verlander, M. S., Klevans, L., O'Donnell, M., Goodman, M., and Melmon, K. L. Conjugates of Catecholamines. II. *In Vitro* and *in Vivo*

- Rosenkranz, R. P.—*Continued*
 Pharmacological Activity of *N*-Alkyl-Functionalized Carboxylic Acid Congeners and Amides Related to Isoproterenol, 429
 Ross, Elliott M. See *Florio*, 195
 Roth, Robert A. See *Wiersma*, 300

S

- Sayer, Jane M. See *Vyas, van Bladeren, Thakker, Yagi, Levin, and Jerina*, 115
 Schein, Philip S. See *Tew, Erickson, White, Wang, and Hartley-Asp*, 324
 Schellenberg, Gerard D., Anderson, Leojean, and Swanson, Philip D. Inhibition of Na^+ - Ca^{2+} Exchange in Rat Brain by Amiloride, 251
 Schultz, Günter See *Aktories and Jakobs*, 183
 Schwartz, Joan P.
 See *Onali, Eva, Olinas, and Costa*, 189
 See *Onali, Olinas, and Costa*, 380
 Schwartz, Rochelle D., and Kellar, Kenneth J. [^3H]Acetylcholine Binding Sites in Brain: Effect of Disulfide Bond Modification, 387
 Seeman, Phillip. See *Lilly, Fraser, Jung, and Venter*, 10
 Selassie, Cynthia Dias. See *Woodson, Ames, Hansch, and Weinshilboum*, 471
 Serabjit-Singh, Cosette. See *Robertson, Croft, and Philpot*, 156
 Shannon, Michael. See *Battaglia and Titeler*, 409
 Sharpless, Norman E. See *Kador*, 521
 Silver, Paul J. See *Miller and Stull*, 235
 Sladeczek, Fritz, Bockaert, Joël, and Mauger, Jean-Pierre. Differences between Agonist and Antagonist Binding to Alpha_1 -Adrenergic Receptors of Intact and Broken-Cell Preparations, 392
 Sokolovsky, Mordechai. See *Henis*, 357
 Strosar, Mira. See *Eyer and Lierheimer*, 282
 Stull, James T. See *Miller and Silver*, 235
 Sturtevant, J. M. See *Herbette and Katz*, 259
 Swanson, Phillip D. See *Schellenberg and Anderson*, 251

T

- Taton, G.
 See *Robberecht, Delhay, De Neef, Waelbroeck, De Smet, Leclerc, Chatelain, and Christophe*, 169
 See *Waelbroeck, Delhay, Chatelain, Camus, Pochet, Leclerc, De Smet, Robberecht, and Christophe*, 174
 Tephly, T. R. See *Makar*, 124
 Tew, Kenneth D., Erickson, Leonard C., White, Geoffrey, Wang, Ann L., Schein, Philip S., and Hartley-Asp, Beryl. Cytotoxicity of Estramustine, a Steroid-Nitrogen Mustard Derivative, through Non-DNA Targets, 324
 Thakker, Dhiren R. See *Vyas, van Bladeren, Yagi, Sayer, Levin, and Jerina*, 115
 Thayer, Stanley A., and Fairhurst, Alan S. The Interaction of Dihydropyridine Calcium Channel Blockers with Calmodulin and Calmodulin Inhibitors, 6
 Thompson, Claudia, and Lucier, George W. Hepatic Estrogen Responsiveness: Possible Mechanisms for Sexual Dimorphism, 69
 Titeler, Milt. See *Battaglia and Shannon*, 409
 Todaro, Louis J. See *Blount, Fryer, and Gilman*, 425
 Tracy, James W., Catto, Brian A., and Webster, Leslie T., Jr. Reductive Metabolism of Niridazole by Adult *Schistosoma mansoni*: Correlation with Covalent Drug Binding to Parasite Macromolecules, 291

U

- Undén, Anders. See *Nordström, Alberts, Westlind, and Bartfai*, 1

V

- van Bladeren, Peter J. See *Vyas, Thakker, Yagi, Sayer, Levin, and Jerina*, 115
 Venter, J. Craig. See *Lilly, Fraser, Jung, and Seeman*, 10

- Verlander, M. S. See *Rosenkranz, Hoffman, Jacobson, Klevans, O'Donnell, Goodman, and Melmon*, 429
 Vyas, Kamlesh P., van Bladeren, Peter J., Thakker, Dhiren R., Yagi, Haruhiko, Sayer, Jane M., Levin, Wayne, and Jerina, Donald M. Regioselectivity and Stereoselectivity in the Metabolism of *trans*-1,2-Dihydroxy-1,2-dihydrobenz[*a*]anthracene by Rat Liver Microsomes, 115

W

- Wachtel, Ruth E., and Wilson, Wilkie A., Jr. Barbiturate Effects on Acetylcholine-Activated Channels in *Aplysia* Neurons, 449
 Waelbroeck, M.
 Taton, G., Delhay, M., Chatelain, P., Camus, J. C., Pochet, R., Leclerc, J. L., De Smet, J. M., Robberecht, P., and Christophe, J. The Human Heart Beta -Adrenergic Receptors. II. Coupling of Beta_2 -Adrenergic Receptors with the Adenylate Cyclase System, 174
 See *Robberecht, Delhay, Taton, De Neef, De Smet, Leclerc, Chatelain, and Christophe*, 169
 Wamsley, James K. See *Zarbin, Palacios, and Kuhar*, 341
 Wang, Ann L. See *Tew, Erickson, White, Schein, and Hartley-Asp*, 324
 Wang, De-Shin. See *Evans, Patierno, Cantoni, and Costa*, 77
 Wanwimolruk, Sompon, Birkett, Donald J., and Brooks, Peter M. Structural Requirements for Drug Binding to Site II on Human Serum Albumin, 458
 Webster, Leslie T., Jr. See *Tracy and Catto*, 291
 Weinshilboum, Richard M. See *Woodson, Ames, Selassie, and Hansch*, 471
 Westlind, Anita. See *Nordström, Alberts, Undén, and Bartfai*, 1
 White, Geoffrey. See *Tew, Erickson, Wang, Schein, and Hartley-Asp*, 324
 White, Steven J., and Jacobs, Robert S. Effect of Stypoldione on Cell Cycle Progression, DNA and Protein Synthesis, and Cell Division in Cultured Sea Urchin Embryos, 500
 Widen, Steven G. See *Denney, Fritz, Patel, and Abell*, 60
 Wiersma, David A., and Roth, Robert A. The Prediction of Benzo[*a*]pyrene Clearance by Rat Liver and Lung from Enzyme Kinetic Data, 300
 Wilkinson, Christopher F. See *Murray, Marcus, and Dubé*, 129
 Wilson, Leslie. See *O'Brien and Jacobs*, 493
 Wilson, Wilkie A., Jr. See *Wachtel*, 449
 Woodson, Lee C., Ames, Matthew M., Selassie, Cynthia Dias, Hansch, Corwin, and Weinshilboum, Richard M. Thiopurine Methyltransferase: Aromatic Thiol Substrates and Inhibition by Benzoic Acid Derivatives, 471
 Wright, Gregory B., Alexander, R. Wayne, Eckstein, Laurie S., and Gimbrone, Michael A., Jr. Characterization of the Rabbit Ventricular Myocardial Receptor for Angiotensin II: Evidence for Two Sites of Different Affinities and Specificities, 213

Y

- Yagi, Haruhiko. See *Vyas, van Bladeren, Thakker, Sayer, Levin, and Jerina*, 115
 Yamazoe, Yasuchi. See *Kamataki, Maeda, Matsuda, Ishii, and Kato*, 146

Z

- Zahler, Warren L. See *Forte and Bylund*, 42
 Zarbin, Marco A., Palacios, Jose M., Wamsley, James K., and Kuhar, Michael J. Axonal Transport of Beta -Adrenergic Receptors: Antero- and Retrogradely Transported Receptors Differ in Agonist Affinity and Nucleotide Sensitivity, 341
 Zeleznikar, Robert J., Jr., Quist, Eugene E., and Drewes, Lester R. An Alpha_1 -Adrenergic Receptor-Mediated Phosphatidylinositol Effect in Canine Cerebral Microvessels, 163
 Ziminski, T. See *Cybulska, Borowski, and Gary-Bobo*, 270
 Zukin, Suzanne. See *Chow*, 203
 Zunino, Franco. See *Gambetta, Colombo, and Lanzi*, 336

CUMULATIVE SUBJECT INDEX¹ FOR VOLUMES 23 AND 24

A

Acetylcholine

- activated neuronal channels, barbiturate effects, **24**, 449
- ³H-labeled, binding sites in brain (rat), **24**, 387
- modulation
 - adenylate cyclase in GH₃ pituitary cells, **24**, 189
 - cyclic AMP content in pituitary GH₃ cells, **24**, 189
 - prolactin secretion in pituitary GH₃ cells, **24**, 189
- muscarinic, **24**, 380
- receptor
 - effect of *cis*-bis-Q (eel), **23**, 344
 - nicotinic, antibiotic inhibition, **23**, 8
- release, **24**, 1
- storage (ray), **24**, 48, 55
- transport
 - effect of tetraphenylborate (ray), **24**, 55
 - in synaptic vesicles (ray), **24**, 48

Acetylcholinesterase

- brain (chicken), **23**, 717
- red blood cell, monoclonal antibodies (human), **24**, 513

ACTH, see Adrenocorticotrophic hormone

Activation

- adenylate cyclase, role of calcium and magnesium ions (rat), **23**, 369
- benzidine, by peroxidases, **23**, 766
- oxidation, mechanisms (rat), **24**, 137

Activity

- adenylate cyclase, synaptic membranes from striatum (rat), **23**, 393
- antiparasitic, niridazole (schistosome), **24**, 291
- aromatic heptaene macrolide antibiotics, on biological and lipidic model membranes, **24**, 270
- cytotoxic, 9-deazaadenosine, in colon carcinoma (human), **24**, 309
- ionophoretic, **24**, 270

Acyclovir, herpes simplex virus sensitivity, **24**, 316Adaptation, cellular, down-regulation and desensitization, **24**, 413

Adenohypophysis

- dopamine receptor (rat), **23**, 576
- effect of muscarinic antagonists on receptor conformations (rat), **24**, 357

Adenosine

- deaminase, lymphocytic (mouse), **23**, 165
- interaction with stimulatory ligands, **24**, 195

S-Adenosylmethionine

- elevation (rat), **24**, 124
- hepatic
 - effect of methionine (rat), **24**, 124
 - effect of nitrous oxide (rat), **24**, 124

Adenylate cyclase

- activity
 - in cultured fibroblasts, **23**, 648
 - in synaptic membranes from striatum (rat), **23**, 393
- adrenal cortex, activation by guanine nucleotides (rat), **23**, 369
- anterior pituitary (rat), **23**, 576
- catalytic component, **24**, 195
- coupling to striatal muscarinic receptors, **24**, 380
- D₂ dopamine receptor binding (rat), **23**, 576
- dopamine inhibition (rat), **23**, 576
- GTP-dependent activity, **23**, 648
- heart, coupling with β_{2A} -adrenergic receptors (human), **24**, 174

- in heart auricles (human), **24**, 174
- in pituitary GH₃ cells, **24**, 189
- inhibition, **24**, 195, 380
- noncoupled with angiotensin II (rabbit), **24**, 213
- somatostatin inhibition, **24**, 183
- spermatozoal, effect of forskolin, **24**, 42
- testicular, effect of forskolin, **24**, 42

Adipose tissue

- content in nonresponsive mice, **24**, 464
- role in hexachlorobiphenyl metabolism (mouse), **24**, 464

Adrenal

- cortex, activation by guanine nucleotides (rat), **23**, 369
- medulla, ascorbic acid secretion (bovine), **23**, 437
- medullary cells
 - calcium uptake (bovine), **23**, 547
 - catecholamine secretion (bovine), **23**, 547
 - catecholamine secretion (bovine), **23**, 671
 - culture (bovine), **23**, 547
 - ion flux (bovine), **23**, 681
- steroidogenesis, inhibition, **23**, 743

Adrenergic receptor

 α_1

- agonist and antagonist binding, **24**, 392
- chlorpromazine antagonism, **23**, 67
- in cerebral microvessels (dog), **24**, 163
- in pituitary neurointermediate lobe (porcine), **24**, 409
- postsynaptic, in tracheal smooth muscle (dog), **23**, 570
- trifluoperazine antagonism, **23**, 67
- turnover in submaxillary glands (rat), **23**, 282
- vas deferens (rat), **23**, 359

 α_2

- in intestinal epithelial cells (rat), **23**, 228
- postsynaptic, in tracheal smooth muscle (dog), **23**, 570

 β

- agonist affinity (rat), **24**, 341
- agonists, nonselective (human), **24**, 169
- axonal transport (rat), **24**, 341
- in erythrocytes (rat), **24**, 174
- in heart (rat), **24**, 174
- in heart auricles (human), **24**, 169
- in reticulocytes (rat), **24**, 174
- interaction with full and partial agonists, **24**, 398
- nucleotide sensitivity (rat), **24**, 341
- on intact L6 muscle cells, **24**, 398
- tracheal smooth muscle, **24**, 235
- β_{2A} , in heart (human), **24**, 174

Adrenocorticotrophic hormone, mechanism of action (rat), **23**, 369

Affinity

- oxotremorine analogues, for ileal muscarinic receptors (guinea pig), **23**, 17
- phenyl *N*-methyl carbamates, quantum mechanical study, **24**, 436
- Aflatoxin B₁, metabolism to promutagen (rat), **24**, 146
- Aggregation, platelet, inhibition by *S*-nitrosothiols (human), **23**, 653
- Aging
 - effect on cytochrome P-450 isoenzymes (rabbit), **23**, 244
 - effect on drug-metabolizing enzymes (rabbit), **23**, 244
- Agonist
 - affinity for β -adrenergic receptors (rat), **24**, 341
 - β -adrenergic
 - full, in heart (human), **24**, 174
 - nonselective (human), **24**, 169
 - partial, in heart (human), **24**, 174

¹ Boldface numbers indicate appropriate volume; lightface numbers indicate pagination.

Agonist—Continued

- beta*₂-selective, binding in heart (human), 24, 169
- binding
 - in caudate nucleus (porcine), 24, 366
 - to *alpha*₁-adrenergic receptors, 24, 392
 - to anterior pituitary (rat), 23, 44
 - temperature dependence, 24, 392
- concentration jumps (eel), 23, 344
- differential effects, 24, 398
- full, interaction with *beta*-adrenergic receptors, 24, 398
- induced changes in nucleotide synthesis and degradation, 23, 384
- kappa*, in thalamus (rabbit), 24, 23
- mu*, in cerebellum (rabbit), 24, 23
- muscarinic
 - ileal (guinea pig), 23, 17
 - partial (guinea pig), 23, 17
- opiate
 - in cerebellum (rabbit), 24, 23
 - in thalamus (rabbit), 24, 23
- partial, interaction with *beta*-adrenergic receptors, 24, 398
- postsynaptic
 - at muscarinic cholinergic synapses, 24, 1
 - muscarinic, 24, 1
 - receptor, high-affinity states (bovine), 23, 295
 - semirigid, effect on nicotinic acetylcholine receptors (frog), 23, 337
- AH5183, *see* 2-(4-Phenylpiperidino)cyclohexanol
- Albumin
 - human serum
 - site II binding site, 24, 458
 - structural requirements for binding, 24, 458
 - production, liver, effect of halothane (rat), 24, 277
- Alcohol, *see also* *Ethanol*
- microsomal *p*-hydroxylation of aniline, 23, 213
- Aldose reductase
 - inhibitor site, pharmacophore requirements, 24, 521
 - inhibitors, design, 24, 521
- Alkaloid
 - ergot, interaction with D-2 dopamine receptors (bovine), 23, 585
 - harmala, ionization, 23, 614
- Alkoxyethylenedioxybenzene, derivatives, interactions with hepatic
 - microsomal mixed-function oxidases (rat), 24, 129
- N*-Alkyl-functionalized congeners and amides related to isoproterenol, 24, 429
- Allosteric interactions in brain (rat), 23, 326
- Amine
 - aromatic
 - metabolism in liver (rabbit), 24, 156
 - mutagenesis (rabbit), 24, 156
 - bound, chromaffin granules (bovine), 23, 431
- Amide, carboxylic acid, related to isoproterenol, 24, 429
- Amiloride, inhibition of Na⁺-Ca²⁺ exchange in brain (rat), 24, 251
- Amino acid
 - adduct, thioacetamide *S*-oxide (rat), 23, 219
 - receptor, acidic, in hippocampus, 24, 222, 229
- 2-Aminoanthracene, mutagenic products (rabbit), 24, 156
- 4-Aminobiphenyl, cytochrome P-450 induction (rat), 24, 146
- γ -Aminobutyric acid
 - antagonist, binding in brain (rat), 24, 326
 - binding, group-selective reagent modification, 23, 52
 - receptor
 - brain-specific binding (rat), 23, 326
 - chloride ion channel complex (rat), 23, 315
 - interactions with benzodiazepine receptor (rat), 23, 315
- γ -Aminobutyric acid-A, brain-specific binding sites (rat), 23, 326
- 5'-Amino-5'-deoxythymidine
 - modulation of iododeoxyuridine cytotoxicity, 23, 709
 - modulation of iododeoxyuridine metabolism, 23, 709
 - preferential inhibition of phosphorylation, 24, 90
- 2-Aminofluorine
 - cytochrome P-450 induction (rat), 24, 146
 - mutagenic products (rabbit), 24, 156
- Aminoglycoside antibiotics, 3-dimensional structure-activity relationship, 23, 127
- 2-Amino-6-methyl-dipyrido(1,2- α :3',2'-*d*)imidazole, polychlorinated biphenyl hydroxylation (rat), 24, 146
- 3-Amino-1-methyl-5*H*-pyrido(4,3-*b*)indole, polychlorinated biphenyl hydroxylation (rat), 24, 146
- p*-Aminophenol, oxidation, catalysis, 23, 461
- Amphetamine, microsomal metabolism (rat), 23, 748
- Amphibian, myelinated axon, 23, 519
- Amylobarbitone, oxidation (human), 23, 474
- Analogue
 - cytosine arabinoside, antileukemic activity, 23, 175
 - dCMP (human), 23, 159
 - 2'-deoxycytidine, antileukemic activity, 23, 175
 - formation, NAD, 23, 534
 - oxotremorine, 24, 1
 - ileal muscarinic receptors (guinea pig), 23, 17
 - substance P, dissociation constant (guinea pig), 23, 558
 - uridine, transport in lymphoblastoid cells (human), 23, 153
- Anemia, sickle cell, hemoglobin solubility, 23, 100
- Anesthetic, local, effect on binding and depolarization in cerebral cortex (guinea pig), 23, 350
- Angiotensin II
 - noncoupled with adenylate cyclase (rabbit), 24, 213
 - receptor
 - regulation, cations and guanine nucleotides (rabbit), 24, 213
 - ventricular myocardial (rabbit), 24, 213
- Aniline, microsomal *p*-hydroxylation, 23, 213
- Anion
 - effect on acetylcholine transport (ray), 24, 55
 - transport, inhibitors, 23, 92
- Ansamycins, structure-activity relationship, 23, 133
- Antagonism
 - dynorphin
 - β -chlornaltrexamine, 23, 36
 - nalozone, 23, 36
 - summation of inhibitory effects, 24, 30
- Antagonist
 - γ -aminobutyric acid, binding in brain (rat), 23, 326
 - beta*-adrenergic
 - in heart (human), 24, 174
 - nonselective (human), 24, 169
 - beta*₁-selective, binding in heart (human), 24, 169
 - binding
 - to *alpha*₁-adrenergic receptors, 24, 392
 - to anterior pituitary (rat), 23, 44
 - calmodulin
 - effect on Ca²⁺ uptake in peritoneal macrophages (guinea pig), 23, 78
 - effect on smooth muscle (bovine), 23, 665
 - folate, tetrahydrobiopterin, 24, 103
 - muscarinic
 - benzilates and tropates, 24, 357
 - effect on receptor conformations in adenohypophysis (rat), 24, 357
 - ileal (guinea pig), 23, 17
 - presynaptic
 - at muscarinic cholinergic synapses, 24, 1
 - muscarinic, 24, 1
 - regulatory, iododeoxyuridine metabolism, 23, 709
 - Ro 15-1788, effect on benzodiazepine receptors (rat), 23, 289
- Anthracycline antibiotics, binding in liver (rat), 24, 336
- Antibiotic(s)
 - aminoglycoside, 3-dimensional structure relationship, 23, 127
 - anthracycline, binding in liver (rat), 24, 336
 - antitumor protein, 23, 500

- aromatic heptaene macrolide
 activity on biological and lipidic model membranes, 24, 270
 electric charge, 24, 270
 effect on nicotinic acetylcholine receptor, 23, 8
 holo-, chromophore, 24, 97
- Antibody, monoclonal
 cholinesterases (human), 24, 513
 molecular activity (human), 24, 60
 monoamine oxidase (human), 24, 60
- Antidepressant
 brain, receptors, 23, 594
 effect on dextromethorphan binding, 23, 629
- Antidiarrheal agents, effect on intestinal epithelial cells (rat), 23, 228
- Antimycin A, effects on parotid gland (rat), 23, 71
- Antipyrine, oxidation (human), 23, 474
- Antitumor drug, α -1,3,5-triglycidyl-*s*-triazinetriene, 23, 182
- Antitussive, effect on dextromethorphan binding, 23, 629
- Antiviral agents, cytotoxicity, 24, 90
- Antiviral mechanism
 acyclovir, 24, 316
 (*E*)-5-(2-bromovinyl)-2'-deoxyuridine, 24, 316
- Anxiolytic, binding in brain (rat), 23, 326
- Apamin, effect in vas deferens (guinea pig), 23, 409
- Apoprotein, neocarzinostatin binding, 23, 500
- Aromatic sulfhydryl methyl acceptors, 24, 471
- Aryl hydrocarbon hydroxylase
 cytochrome P-450 (rat), 24, 129
 induction in fibroblasts (mouse), 23, 198
 reconstituted system (guinea pig), 23, 258
- Ascaris suum*, glycogen metabolism, cyclic AMP-mediated regulation, 23, 378
- Ascorbic acid
 compartmentalization (bovine), 23, 437
 secretion (bovine), 23, 437
 by chromaffin cells (bovine), 23, 437
- Atenolol, binding in heart (human), 24, 169, 174
- ATP, ^3H -labeled
 binding, 23, 1
 divalent ion-specific binding (rabbit), 23, 1
- ATPase, divalent ion, 23, 1
- Atrium, phosphatidylinositol metabolism (mouse), 24, 351
- Auricle, heart, β -adrenergic receptors (human), 24, 169, 174
- Auromomycin
 DNA damage, 24, 97
 effect on HeLa S₃ nuclei, 24, 97
- Axon, myelinated
 amphibian, 23, 519
 effect of scorpion neurotoxins, 23, 519
- Axonal transport, β -adrenergic receptors (rat), 24, 341
- 5-Azadeoxycytidine, inhibition of DNA methylation, 24, 109
- 5-Azadeoxycytidine 5'-triphosphate
 DNA methylase, 24, 109
 DNA polymerase, 24, 109
- 6-Azaauridine, transport, in lymphoblastoid cells (human), 23, 153
- B**
- Barbiturate
 binding
 in brain, 23, 52
 in brain (rat), 23, 326
 effects on acetylcholine-activated neuronal channels, 24, 449
 receptor, interactions with benzodiazepine receptor (rat), 23, 315
- Batrachotoxin-induced depolarization in cerebral cortex (guinea pig), 23, 350
- Batrachotoxinin-A, ^3H -labeled, binding in cerebral cortex (guinea pig), 23, 350
- BC₃H₁ cell, agonist and antagonist binding to α ₁-adrenergic receptors, 24, 392
- Benz[*a*]anthracene, induction of cytochrome P-450 in fibroblasts (mouse), 23, 198
- Benzidine, activation by peroxidases, 23, 766
- 20 α -Benzoate, binding in cerebral cortex (guinea pig), 23, 350
- Benzodiazepine
 antagonist, Ro 15-1788 (rat), 23, 289
 binding
 group-selective reagent modification, 23, 52
 sites, water solubility (rat), 23, 310
 endogenous inhibitor competition *in vivo* (rat), 23, 310
 receptor
 binding, extraction in distilled water (rat), 23, 310
 binding kinetics (rat), 23, 289
 brain-specific (rat), 23, 326
 conformational change (rat), 23, 289
 endogenous inhibitor(s) (rat), 23, 310
 interactions with γ -aminobutyric acid and barbiturate receptor sites (rat), 23, 315
 ligand interactions, 24, 425
 subtypes (rat), 23, 315
 1,4-Benzodiazepines, conformational recognition of receptor, 24, 425
- Benzoic acid, derivatives, effect on thiopurine methyltransferase, 24, 471
- Benzo[*a*]pyrene
 clearance, prediction (rat), 24, 300
 cytochrome P-450 induction (rat), 24, 146
 liver metabolism (rat), 24, 300
 lung metabolism (rat), 24, 300
 metabolism, product inhibition, 23, 735
- Benzphetamine
 metabolism, in hepatic microsomes (rat), 23, 748
 sequential oxidation (rat), 23, 748
- N*-Benzylethyl- α -phenylnitron, microsomal metabolism (rat), 23, 748
- Betamethasone
 activation of monooxygenases (rat), 24, 137
 -mediated activation of biphenyl 2-hydroxylation (rat), 24, 137
- Binding
 [^3H]acetylcholine, in brain (rat), 24, 387
 agonist
 temperature dependence, 24, 392
 to α ₁-adrenergic receptors, 24, 392
 γ -aminobutyric acid, group-selective reagent modification, 23, 52
 antagonist, to α ₁-adrenergic receptors, 24, 392
 anthracycline antibiotics, in liver (rat), 24, 336
 ^3H -ATP, 23, 1
 benzodiazepine, group-selective reagent modification, 23, 52
 1,4-benzodiazepines, conformational recognition of receptor, 24, 425
 [^{35}S]- γ -butylbicyclophosphorothionate, to brain-specific sites (rat), 23, 326
 cocaine
 in brain (mouse, rat), 23, 600
 in platelets (human), 23, 600
 covalent
 4-dimethylaminophenol, to hemoglobin (human), 24, 282
 mechanism, 24, 182
 site in hemoglobin (human), 24, 282
 cytochrome P-450, mechanism, 23, 213
 dextromethorphan
 effect of antidepressants, 23, 629
 effect of antitussives, 23, 629
 effect of diphenylhydantoin, 23, 629
 effect of noscapine, 23, 629
 effect of phenothiazines, 23, 629
 [^3H]dextromethorphan
 in brain (guinea pig), 23, 619
 in brain and liver (guinea pig), 23, 629
 dextrorphan, in brain (guinea pig, rat), 23, 619
 diazepam, conformation for, 24, 425

Binding—Continued

- divalent ion-specific, of ^3H -ATP (rabbit), 23, 1
 - dopamine receptor (bovine), 23, 295
 - DNA, neocarzinostatin chromophore, 23, 500
 - drug
 - covalent (schistosoma), 24, 291
 - energy-dependent (human), 24, 485
 - fatty acid study, 24, 458
 - hydrophobic, 24, 324
 - structural requirements, 24, 458
 - estramustine, to nuclear matrix, 24, 324
 - estrogen, hepatic (rat), 24, 69
 - ethylketocyclazocine, to neurotumor cells, 23, 486
 - guanine nucleotides
 - in adrenal membranes (rat), 23, 369
 - role of calcium ion (rat), 23, 369
 - ^3H imipramine, 23, 607
 - ion recognition sites, brain-specific (rat), 23, 326
 - kinetics, benzodiazepine (rat), 23, 289
 - ^{125}I -labeled cobra α -toxin, 23, 8
 - ligand-receptor interactions (bovine), 23, 585
 - ^3H mepyramine
 - temperature dependence, 23, 60
 - to histamine H_1 receptor, 23, 60
 - ^3H cis-methyldioxolane
 - in caudate nucleus (porcine), 24, 374
 - to guanyl nucleotide-sensitive sites (porcine), 24, 366
 - multiple states (bovine), 23, 585
 - muscarinic receptors, modification by gallamine (rat), 23, 551
 - quinazolines, conformation for, 24, 425
 - radioligand, tracheal (dog), 23, 570
 - Ro 11-2465, 23, 607
 - site(s)
 - ^3H acetylcholine (rat), 24, 387
 - β -adrenergic receptors in heart (human), 24, 169, 174
 - benzodiazepine, water solubility (rat), 23, 310
 - cardiac muscarinic receptor (rat), 24, 15
 - κ opiate, regional distribution (rabbit), 24, 23
 - opiate, in central nervous system (rabbit), 24, 23
 - serotonin, 23, 594
 - ^3H spiroperidol
 - in striatum (rat), 23, 303
 - thermodynamics (rat), 23, 303
 - tetrabenazine, chromaffin granules (bovine), 23, 431
 - ^3H tetrahydrotrazodone, 23, 594
 - ^3H yohimbine (rat), 23, 228
- Biochemical analysis
- in study of effect of chlorpromazine (human), 23, 771
 - in study of erythrocyte membrane protein (human), 23, 771
- Biosynthesis, tetrahydrobiopterin, 24, 103
- Biotransformation, phenol, by liver microsomes (rat), 23, 453
- Biphenyl
- hydroxylation
 - cumene hydroperoxide (rat), 24, 137
 - K_m and V_{max} (rat), 24, 137
 - 2-hydroxylation
 - betamethasone-mediated (rat), 24, 137
 - mechanisms (rat), 24, 137
 - polychlorinated, induction of high-spin form of cytochrome P-450 (rat), 24, 146
- cis-Bis-Q. See cis-3,3'-Bis-[α -(trimethylammonium)methyl]azobenzene
- cis-3,3'-Bis-[α -(trimethylammonium)methyl]azobenzene, purification and properties, 23, 344
- Bladder, urinary
- divalent ion-specific binding of ^3H -ATP (rabbit), 23, 1
 - smooth muscle (rabbit), 23, 1
- Blood flow, benzo[a]pyrene clearance (rat), 24, 300
- Bond, disulfide, effect on ^3H acetylcholine binding (rat), 24, 387

Brain

- ^3H acetylcholine binding sites (rat), 24, 387
- α -adrenergic receptors (porcine), 24, 409
- antidepressants, receptors, 23, 594
- carboxylesterases, inhibition (chicken), 23, 717
- cocaine binding (mouse, rat), 23, 600
- cortex, muscarinic receptors (rat), 24, 357
- dextromethorphan binding (guinea pig), 23, 629
- dopamine receptors (dog, human), 24, 10
- ^3H flunitrazepam binding sites, solubility (rat), 23, 310
- high-affinity dextromethorphan binding sites
 - regional distribution (guinea pig), 23, 619
 - subcellular distribution (guinea pig), 23, 619
- medulla-pons, muscarinic receptors (rat), 24, 357
- microtubule assembly, inhibition by stypoldione (bovine), 24, 493
- Na^+ - Ca^{2+} exchange (rat), 24, 251
- nicotinic cholinergic receptor (rat), 24, 387
- opiate receptor, μ and κ subtypes (rat), 24, 203
- serotonergic neurons (mouse, rat), 23, 600
- specific [^{35}S]t-butylbicyclophosphorothionate binding sites (rat), 23, 326
- Bromobenzene metabolism, glutathione (rat), 23, 235
- (E)-5-(2-Bromovinyl)-2'-deoxyuridine, herpes simplex virus sensitivity, 24, 316
- Butaclamol, conformational properties, 24, 243
- Butylated hydroxyanisole, effect on benzidine oxidation, 23, 766
- t-Butylbicyclophosphorothionate, ^{35}S -labeled, binding to brain-specific sites (rat), 23, 326
- t-Butylphosphorothionate, affinity binding (rat), 23, 326
- γ -Butyrolactone, receptor, computer-assisted modeling, 23, 511
- Butyrylcholinesterase, plasma, monoclonal antibodies (human), 24, 513

C

 Ca^{2+} , see also Calcium

- dependent cyclic AMP accumulation, regulation in pituitary tumor cells (rat), 23, 399
 - intracellular, accumulating system in peritoneal macrophages (guinea pig), 23, 78
 - metabolism, in pituitary tumor cells (rat), 23, 399
 - mobilization, in GH $_3$ cells (rat), 23, 399
 - Na^+ , exchange in brain (rat), 24, 251
 - transport in brain (rat), 24, 251
 - uptake in peritoneal macrophages (guinea pig), 23, 78
- Cadmium
- growth inhibition, 24, 77
 - resistant cells, 24, 77
- Calcium, see also Ca^{2+}
- activated potassium conductance (guinea pig), 23, 409
 - channel blockers, 24, 6
 - effect on beating in heart cells in culture, 23, 417
 - exchange, in heart cells, 23, 417
 - ion
 - role in adenylate cyclase activation (rat), 23, 369
 - role in guanine nucleotide binding (rat), 23, 369
 - mobilization in parotid gland (rat), 23, 71
 - pump, inhibition by ouabain (bovine), 23, 681
 - release, myocardial cell membrane, 23, 417
 - uptake
 - in adrenal medullary cells (bovine), 23, 547
 - myocardial cell membrane, 23, 417
- Calmodulin
- antagonist
 - effect on Ca^{2+} uptake in peritoneal macrophages (guinea pig), 23, 78
 - effect on smooth muscle (bovine), 23, 665
 - effect
 - in tracheal smooth muscle, 24, 235
 - on Ca^{2+} uptake in peritoneal macrophages (guinea pig), 23, 78

- inhibitors, interaction with calcium channel blockers, 24, 6
 interaction with calcium channel blockers, 24, 6
 Calorimetry, model membranes, partitioning, 24, 259
 Cannabinoids
 effects on prostaglandin synthesis (human), 23, 121
 stimulation of arachidonate release (human), 23, 121
 Cannabis, effect on prostaglandin synthesis (human), 23, 121
 Carbamylcholine, effect on $^{22}\text{Na}^+$ permeability, 23, 8
 Carbinolamine, intermediate, in *N*-demethylation reactions, 23, 758
 Carbon tetrachloride
 effect of long-term administration on hepatic mtDNA polymerase (mouse), 24, 329
 liver regeneration after treatment (mouse), 24, 329
 Carboxylesterase, brain (chicken), 23, 717
 Carboxylic acid
 amides, related to isoproterenol, 24, 429
 congeners, related to isoproterenol, 24, 429
 Carboxymethylation, protein, nitrous oxide (rat), 24, 124
 Carcinogenesis, polycyclic aromatic hydrocarbons (rat), 24, 115
 Carcinogenicity
 2,4-dideuterioestradiol (hamster), 23, 278
 2-fluoroestradiol (hamster), 23, 278
 4-fluoroestradiol (hamster), 23, 278
 Carcinoma, colon
 cell culture (human), 24, 309
 cytotoxic activity of 9-deazaadenosine (human), 24, 309
 effect of 5-fluorouracil and 5-fluorouridine (human), 23, 540
 effect of sangivamycin on cells (human), 24, 509
 Catalysis
 N-demethylation reactions, 23, 758
 4-hydroxylation of debrisoquine (human), 23, 474
 Catalytic component, adenylate cyclase, 24, 195
 Catechol formation in liver (rat), 23, 453
 Catecholamine
 carrier, chromaffin granules (bovine), 23, 431
 conjugates, 24, 429
 ionization, chromaffin granules (bovine), 23, 431
 secretion (bovine), 23, 437
 in adrenal medullary cells (bovine), 23, 547, 671, 681
 ouabain stimulation (bovine), 23, 671
 storage vesicle, chromaffin cell (bovine), 23, 437
 Cation
 effect
 on angiotensin II receptor (rabbit), 24, 213
 on dextromethorphan binding (guinea pig), 23, 619
 on [^3H]cis-methyldioxolane binding to guanyl nucleotide-sensitive sites (porcine), 24, 366
 divalent
 receptor in salivary gland membrane (rat), 23, 563
 regulation of substance P binding in salivary membranes (rat), 23, 563
 Caudate nucleus, muscarinic receptor (porcine), 24, 366, 374
 Cell
 adrenal medullary
 calcium uptake (bovine), 23, 547
 catecholamine secretion (bovine), 23, 547, 671
 culture (bovine), 23, 547
 effect of ouabain (bovine), 23, 671, 681
 BC $_3$ H $_4$, agonist and antagonist binding to α_1 -adrenergic receptors, 24, 392
 broken preparation, agonist and antagonist binding to α_1 -adrenergic receptors, 24, 392
 C3H/10T1/2, cytochrome P-450 induction (mouse), 23, 198
 cadmium-resistant, 24, 77
 Chinese hamster ovary, tiazofurin inhibition, 23, 534
 chromaffin, ascorbic acid secretion (bovine), 23, 437
 colon carcinoma
 culture (human), 24, 309
 cytotoxic activity of 9-deazaadenosine (human), 24, 309
 effect of sangivamycin (human), 24, 509
 HT-29, *in vitro* translation of mRNA (human), 23, 540
 culture, 23, 486
 division, inhibition (sea urchin), 24, 500
 epithelial, intestinal, α_2 -adrenergic receptor (rat), 23, 228
 erythrocyte, monoclonal antibodies to acetylcholinesterase (human), 24, 513
 5-fluorouracil activity, 23, 190
 folate cofactor pools, 23, 190
 heart
 in culture, effect of calcium on beating, 23, 417
 in culture, effect of halothane on beating, 23, 417
 HeLa, DNA metabolism, 23, 171
 HeLa S $_3$
 effects of auromomycin, 24, 97
 nuclear chromatin, 23, 493
 hepatoma
 variant, glucocorticoid-inducible gene (rat), 23, 779
 wild-type, glucocorticoid-inducible gene (rat), 23, 779
 herpes simplex virus-infected, 24, 90
 intact
 agonist and antagonist binding to α_1 -adrenergic receptors, 24, 392
 dopamine receptor binding on (bovine), 23, 295
 isolated
 adrenal medulla (bovine), 23, 671
 effect of ouabain (bovine), 23, 681
 lymphoblastoid, transport of uridine and 6-azauridine (human), 23, 153
 S49 lymphoma, *cyc* $^-$ and H21a variants, 24, 183
 mammalian, cultured, nucleoside transport, 24, 479
 muscle, L6
 intact, 24, 398
 interactions of full and partial agonists with β -adrenergic receptors, 24, 398
 NCB-20 hybrid, ethylketocyclazocine binding, 23, 486
 neoplastic, cultured, transport activity, 24, 479
 neuroblastoma \times glioma NG108-15 hybrid, opiate regulation of cyclic AMP levels, 23, 26
 pituitary, GH $_3$
 adenylate cyclase, 24, 189
 cyclic AMP content, 24, 189
 prolactin secretion, 24, 189
 sickle
 hemoglobin solubility, 23, 100
 2-imidazoline treatment (human), 23, 731
 survival, after exposure to mercury and X-rays, 24, 84
 Central nervous system, multiple opiate binding sites (rabbit), 24, 23
Centruroides sculpturatus, venom neurotoxins, 23, 519
 Cerebellum
 membranes (rabbit), 24, 23
 mu opiate agonists (rabbit), 24, 23
 Cerebral cortex
 [^3H]batrachotoxinin-A binding (guinea pig), 23, 350
 20 α -benzoate binding (guinea pig), 23, 350
 microvessels
 α_1 -adrenergic receptor (dog), 24, 163
 phosphatidylinositol effect (dog), 24, 163
 Chemotherapy
 implications (human), 23, 159
 malaria, 23, 92
 Chinese hamster ovary cell, tiazofurin inhibition, 23, 534
 Chloramphenicol
 cytochrome P-450 inhibition (rat), 23, 445
 effect on hepatic cytochrome P-450 (rat), 23, 445
 Chloride, ion channel- γ -aminobutyric acid complex (rat), 23, 315
 β -Chlornaltrexamine, dynorphin antagonism, 23, 36

- Chlorpromazine
 antagonism, α_1 -adrenergic effects, 23, 67
 effect on proteins in erythrocyte membranes (human), 23, 771
 Cholera toxin, effect on GTPase activity in striatal membranes (rat), 24, 380
 Cholesterol
 side-chain cleavage, 23, 743
 synaptic membrane content (mouse), 23, 86
 Cholinergic receptor, nicotinic, in brain (rat), 24, 387
 Cholinergic synaptic vessels (ray), 24, 55
 acetylcholine transport (ray), 24, 48
 Cholinesterase
 immunochemical comparisons (human), 24, 513
 inhibitors, structure-activity relationships, 24, 436
 monoclonal antibodies (human), 24, 513
 Cholinolytic, presynaptic (ray), 24, 48
 Chromaffin cell
 adrenomedullary, ascorbic acid secretion (bovine), 23, 437
 primary culture (bovine), 23, 437
 Chromaffin granules, catecholamine carrier (bovine), 23, 431
 Chromatin
 HeLa S₃ nuclei, effects of neocarzinostatin, 23, 493
 single-strand breaks, linker, 23, 493
 soluble, release, 24, 97
 Chromatography, high-performance liquid, purification of *cis*-bis-Q (eel), 23, 344
 Chromophore
 degradation of chromatin, 23, 493
 neocarzinostatin, binding to DNA, 23, 500
 nonprotein, 23, 500
 Circular dichroism, neocarzinostatin chromophore, 23, 500
 Clearance, benzo[*a*]pyrene, prediction (rat), 24, 300
 Cleavage, side-chain, cholesterol, 23, 743
 Clone, BC3H-1 muscle cell line, 23, 8
 Clonidine, effect on cyclic AMP in intestinal epithelial cells (rat), 23, 228
 Cocaine
 binding
 in brain (mouse, rat), 23, 600
 in platelets (human), 23, 600
 N-demethylation (mouse), 23, 482
 metabolism (mouse), 23, 482
 toxicity (mouse), 23, 482
 Colon
 carcinoma, cytotoxic activity of 9-deazaadenosine (human), 24, 309
 carcinoma cells
 culture (human), 24, 309
 effect of 5-fluorouracil and 5-fluorouridine (human), 23, 540
 effect of sangivamycin (human), 24, 509
 Complex
 diphenylhydantoin-9-ethyladenine, crystal structure, 23, 273
 hydrogen-bonded, crystal structure, 23, 273
 Complexation, metal, with rifamycins, 23, 133
 Computer-assisted modeling
 γ -butyrolactone receptor, 23, 511
 picrotoxinin receptor, 23, 511
 Conformation
 butaclamol, 24, 243
 fortimicins, 23, 127
 isobutaclamol, 24, 243
 receptor, adenohipophyseal, effect of muscarinic antagonists (rat), 24, 357
 sodium rifamycin SV, 23, 133
 Conformational change, benzodiazepine receptors (rat), 23, 289
 Conformer, biologically active, 24, 243
 Congener, carboxylic acid, related to isoproterenol, 24, 429
 Conjugate, catecholamine, 24, 429
 Contraction, smooth muscle, α -adrenergic (dog), 23, 570
 Convulsants, cage (rat), 23, 326
 Copper, growth inhibition, 24, 77
 Coronary artery, phosphodiesterase inhibitors (bovine), 23, 424
 Covalent binding, protein (rat), 23, 219
 Cross-linking, intramolecular, 24, 282
 Crystal structure, diphenylhydantoin-9-ethyladenine complex, 23, 273
 Crystallography, X-ray, conformation of neuroleptics, 24, 243
 Culture
 cell, 23, 486
 adrenal medullary (bovine), 23, 547
 colon carcinoma (human), 24, 309
 fibroblasts, adenylate cyclase activity, 23, 648
 heart, beating, 23, 417
 neoplastic, transport activity, 24, 479
 Plasmodium falciparum, growth suppression *in vitro*, 23, 92
 Cumene hydroperoxide, biphenyl hydroxylation (rat), 24, 137
 Cyclic AMP
 accumulation
 Ca²⁺ regulation in GH₃ cells (rat), 23, 399
 in epithelial cells (rat), 23, 228
 in GH₃ cells (rat), 23, 399
 activity in cultured fibroblasts, 23, 648
 Ca²⁺-dependent accumulation, regulation in pituitary tumor cells (rat), 23, 399
 cellular, opiate regulation, 23, 26
 content in pituitary GH₃ cells, 24, 189
 coronary artery cells (bovine), 23, 424
 -dependent protein kinase, 24, 235
 alteration (rat), 23, 641
 Type I (rat), 23, 641
 Type II (rat), 23, 641
 -dependent polyamine enzymes, alteration (rat), 23, 641
 metabolism, muscarinic cholinergic receptor-mediated, 23, 384
 regulation of glycogen metabolism (*Ascaris*), 23, 378
 tracheal smooth muscle, 24, 235
 Cyclic GMP
 accumulation (human), 23, 653
 coronary artery cells (bovine), 23, 424
 heme stimulation (human), 23, 653
 muscarinic stimulation, 24, 1
 Cyclosporin A, lymphocyte sensitivity, 23, 703
 Cysteine conjugate β -lyase (rat), 23, 761
 Cytochalasin B, effect on 3-*O*-methyl-D-glucose in isolated hepatocytes (rat), 23, 141
 Cytochrome
 P-448, 3-methylcholanthrene-inducible (rat), 23, 252
 P-450
 activation (rat), 24, 137
 aryl hydrocarbon hydroxylase (rat), 24, 129
 -dependent monooxygenases, destruction (mouse, rat), 23, 206
 epoxidation of benzo-ring diol epoxides (rat), 24, 115
 forms 2, 4, and 5 (rabbit), 24, 156
 form 5, effect of β -naphthoflavone (rabbit), 24, 156
 hepatic (rabbit), 24, 156
 hepatic, catalytic characterization (rat), 24, 146
 hepatic, *N*-demethylation, 23, 758
 hepatic, *N*-demethylation of cocaine (mouse), 23, 482
 hepatic, 4-hydroxylation catalysis (human), 23, 474
 hepatic, immunochemical quantitation (rat), 24, 146
 hepatic, in benzo[*a*]pyrene clearance (rat), 24, 300
 hepatic, isozymes (rabbit), 24, 156
 hepatic, isozymes (rat), 23, 265, 748
 hepatic, 3-methylcholanthrene-induced (guinea pig), 23, 258
 hepatic, phenol metabolism (rat), 23, 453
 hepatic, role in *N*-demethylation, 23, 758
 hepatic, suicide inactivation (rat), 23, 445
 hepatocytic (rat), 23, 235
 high-spin form (rat), 23, 146

- induction in C3H/10T1/2 fibroblasts (mouse), 23, 198
 isoenzymes, induction and aging (rabbit), 23, 244
 isozymes (rabbit), 24, 156
 isozymes (rat), 23, 748
 mechanism of binding to, 23, 213
N-oxidation (mouse), 23, 482
 phenobarbital induction (rat), 23, 265
 purification (guinea pig), 23, 258
 pulmonary, in benzo[*a*]pyrene clearance (rat), 24, 300
 quantitation (rabbit), 23, 244
 reduction complex (rat), 23, 467
 renal, localization (mouse, rat), 23, 206
 substrate specificity (human), 23, 474
 xylene induction (rat), 23, 265
 P-450_c, active site (rat), 24, 115
 P-450_{acc}
 -dependent cholesterol cleavage, 23, 743
 inhibition, 23, 743
 Cytosine arabinoside, analogues, antileukemic activity, 23, 175
 Cytotoxicity, *see also* Toxicity
 antagonism, 24, 90
 estramustine, 24, 324
 iododeoxyuridine, 23, 709
 mercury (II), 24, 84
 3-methylcholanthrene metabolites (mouse), 23, 198
 X-rays, 24, 84
- ## D
- Daunorubicin-binding protein from liver (rat), 24, 336
 dCMP
 analogues (human), 23, 159
 deaminase (human), 23, 159
 Deaminase
 adenosine, lymphocytic (mouse), 23, 165
 dCMP (human), 23, 159
 deoxycytidylate, substrate and regulator specificity (human), 23, 159
 9-Deazaadenosine
 cytotoxic activity in colon carcinoma (human), 24, 309
 effects on nucleic acids in colon carcinoma (human), 24, 309
 effects on protein synthesis in colon carcinoma (human), 24, 309
 7-Deaza-7-carboxamidoadenosine, *see* Sangivamycin
 Deazapterin, inhibition of tyrosine hydroxylase (bovine), 23, 104
 Debrisoquine, 4-hydroxylation (human), 23, 474
 Deethylation, ethoxycoumarin (rat), 23, 235
 Degradation, chromatin
 by chromophore, 23, 493
 by neocarzinostatin, 23, 493
 Demethylation, mechanism (mouse), 23, 482
N-Demethylation
 carbinolamine intermediate, 23, 758
 cocaine (mouse), 23, 482
 cytochrome P-450-catalyzed, 23, 758
 Denervation, effect on hippocampal receptors, 24, 229
 2'-Deoxycoformycin, toxicity in spleen lymphocytes (mouse), 23, 165
 2'-Deoxycytidine, analogues, antileukemic activity, 23, 175
 Deoxycytidine kinase, role in antileukemic activity, 23, 175
 Deoxycytidylate deaminase, substrate and regulator specificity (human), 23, 159
 Deoxyhemoglobin S, solubility, effect of phenylalanine derivatives, 23, 100
 Depletion, nonprotein, thiol (schistosoma), 24, 291
 Depolarization, batrachotoxin-induced, in cerebral cortex (guinea pig), 23, 350
 Desensitization
 cyclic AMP metabolism, 23, 384
 intrinsic activity-dependent, homologous, 24, 413
 Development, acidic amino acid receptors in hippocampus during, 24, 229
 Dexamethasone, effect on 3-*O*-methyl-D-glucose uptake in isolated hepatocytes (rat), 23, 141
 Dextromethorphan binding
 effect of antidepressants, 23, 629
 effect of antitussives, 23, 629
 effect of diphenylhydantoin, 23, 629
 effect of noscapine, 23, 629
 effect of phenothiazines, 23, 629
 Dextromethorphan binding
 high-affinity
 in brain, 23, 629
 in brain (guinea pig), 23, 619
 Dextrorphan binding, in brain (guinea pig), 23, 619
 Diabetes, complications, control, 24, 521
 Dialysis, equilibrium, in study of drug binding, 24, 458
 Diazepam
 conformation for binding, 24, 425
 effect on [³H]flunitrazepam binding sites (rat), 23, 310
 2',5'-Dideoxyadenosine, interaction with stimulatory ligands, 24, 195
 2,4-Dideuteroestradiol
 carcinogenicity (hamster), 23, 278
 estrogenicity (hamster), 23, 278
 Diethylnitrosamine
 effect of long-term administration on hepatic mtDNA polymerase (mouse), 24, 329
 oval cell proliferation after long-term treatment (mouse), 24, 329
 Diffusion, accelerative exchange (human), 23, 146
 Dihydrofolate reductase
 hepatic
 effects of methotrexate (rat), 23, 724
 effects of nitrous oxide (rat), 23, 724
 inhibitors, 24, 103
 Dihydropyridine, calcium channel blockade, 24, 6
trans-1,2-Dihydroxy-1,2-dihydrobenzo[*a*]anthracene, metabolism (rat), 24, 115
 4-Dimethylaminophenol, covalent binding to hemoglobin (human), 24, 282
 Dimorphism, sexual, mechanisms (rat), 24, 69
 Diphenylhydantoin
 effect on dextromethorphan binding, 23, 629
 9-ethyladenine complex, crystal structure, 23, 273
 Dissociation constant
 determination by pharmacological procedures (guinea pig), 23, 558
 substance P (guinea pig), 23, 558
 substance P analogues (guinea pig), 23, 558
 Distribution, electron, in tetramethylammonium ion, 24, 443
 Disulfide bond, effect on [³H]acetylcholine binding (rat), 24, 387
 DNA
 binding, neocarzinostatin chromophore, 23, 500
 dihydril oxide modifications, 23, 735
 effect on microsomal benzo[*a*]pyrene metabolism, 23, 735
 metabolism, in HeLa cells, 23, 171
 methylase, inhibition by 5-azadeoxycytidine, 24, 109
 non-targets, cytotoxicity of estramustine, 24, 324
 polymerase, 5-azadeoxycytidine 5'-triphosphate, 24, 109
 quinone intercalation, 23, 735
 repair, 24, 84
 single-strand breaks, 24, 84
 synthesis
 inhibition, 23, 698
 in lymphocytes (mouse), 23, 165
 Dopamine
 β-hydroxylase
 chromaffin cell (bovine), 23, 437
 metabolic clearance rate (rat), 23, 112
 inhibition of adenylate cyclase (rat), 23, 576
 receptor
 adenohypophyseal (rat), 23, 576

- Dopamine—*Continued*
 receptor—*Continued*
 agonist/antagonist interactions (rat), 23, 303
 binding on intact cells (bovine), 23, 295
 D₂, anterior pituitary (bovine), 23, 585
 D₂, characterization (rat), 23, 576
 D₂, molecular size (dog, human), 24, 10
 D₂, relationship to other neurotransmitters (dog, human), 24, 10
 D₂, size (dog, human), 24, 10
 D₂, structure (dog, human), 24, 10
 in brain (dog, human), 24, 10
 molecular weight (dog, human), 24, 10
 thermodynamics (rat), 23, 303
 Down-regulation, agonist-specific, homologous, temperature-dependent, 24, 413
 Drug
 antimitotic, 24, 324
 antischistosomal, 24, 291
 binding
 covalent (schistosome), 24, 291
 energy-dependent (human), 24, 485
 fatty acid study, 24, 458
 hydrophobic, 24, 324
 structural requirements, 24, 458
 -membrane interactions, 24, 259
 -metabolizing enzymes, hepatic microsomal (rabbit), 23, 244
 modified sensitivities, herpes simplex virus, 24, 316
 oxidation, polymorphism (human), 23, 474
 resistance, mechanism (human), 24, 485
 Dynorphin
 β -chlornaltrexamine antagonism, 23, 36
 receptor
 ileum (guinea pig), 23, 36
 vas deferens (mouse), 23, 36
 spare receptor fraction, potency, 23, 36
- E**
- Electric charge, aromatic heptaene macrolide antibiotics, 24, 270
 Electric organ
 acetylcholine transport (ray), 24, 48
 acetylcholine transport (ray), 24, 55
 Electron distribution, in tetramethylammonium ion, 24, 443
 Electron paramagnetic resonance, in study of ethanol tolerance (mouse), 23, 86
 Electron spin resonance
 in study of benzidine activation, 23, 766
 in study of effect of chlorpromazine (human), 23, 771
 in study of erythrocyte membrane protein (human), 23, 771
 in study of oxidation of *p*-aminophenol, 23, 461
 Electron transport, enhanced (rat), 24, 137
 Electroplaque, *Electrophorus*, acetylcholine receptors, 23, 344
 Elution, alkaline, 24, 84
 Embryo, development, effect of stypoldione (sea urchin), 24, 500
 Empirical force field, fortimicin, 23, 127
 Endoplasmic reticulum, Ca²⁺ transport (guinea pig), 23, 78
 Energy
 -dependent drug binding (human), 24, 485
 -dependent *Vinca* alkaloid retention (human), 24, 485
 Enzyme
 drug-metabolizing
 effect of aging (rabbit), 23, 244
 hepatic microsomal (rabbit), 23, 244
 inactivation, cytochrome P-450 (rat), 23, 445
 interaction of full and partial inhibitors, 24, 30
 kinetics, liver and lung (rat), 24, 300
 polyamine, alteration (rat), 23, 641
 Epinephrine
 effect on epithelial cyclic AMP levels (rat), 23, 228
 nonselective β -adrenergic agonist, binding in heart (human), 24, 169
- Epoxide hydrolase, hepatic (rat), 24, 115
 Equilibrium dialysis, in study of drug binding, 24, 458
 Ergot, alkaloid, interaction with D-2 dopamine receptors (bovine), 23, 585
 Erythrocyte
 acetylcholinesterase, monoclonal antibodies (human), 24, 513
 β -adrenergic receptors (rat), 24, 174
 lysis, induction by aromatic heptaene macrolide antibiotics, 24, 270
 membrane
 anion transport inhibitors, 23, 92
 protein, effect of chlorpromazine (human), 23, 771
 nucleoside transport mechanism, interaction with 2'-halogeno-2'-deoxyuridines (human), 23, 146
 Ester, phorbol, tumor-promoting, 23, 703
 Esterase, neurotoxic (chicken), 23, 717
 Estramustine, cytotoxicity, through non-DNA targets, 24, 324
 Estrogen
 binding, hepatic (rat), 24, 69
 hepatic responsiveness (rat), 24, 69
 receptor, hepatic (rat), 24, 69
 Estrogenicity
 2,4-dideuterioestradiol (hamster), 23, 278
 2-fluoroestradiol (hamster), 23, 278
 4-fluoroestradiol (hamster), 23, 278
 Ethanol, *see also* Alcohol
 chronic treatment, effect on synaptic membrane order (mouse), 23, 86
 in vitro effects on synaptosomal membrane order (mouse), 23, 86
 Ethoxycoumarin, deethylation (rat), 23, 235
 9-Ethyladenine-diphenylhydantoin complex, crystal structure, 23, 273
 Ethylketocyclazocine, ³H-labeled, binding to neurotumor cells, 23, 486
 N-Ethylmaleimide, effects on [³H]*cis*-methyldioxolane binding to guanyl nucleotide-sensitive and insensitive sites (porcine), 24, 374
 Etorphine, ³H-labeled, opiate inhibition of binding (rabbit), 24, 23
 Excitation-secretion coupling, chromaffin cell (bovine), 23, 437
 Exocytosis
 catecholamine, adrenal medullary cells (bovine), 23, 547
 chromaffin cell (bovine), 23, 437
- F**
- FAD-containing monooxygenase
 N-demethylation of cocaine (mouse), 23, 482
 N-oxidation (mouse), 23, 482
 Fatty acid, in study of drug binding, 24, 458
 Fenmetozole, anti-sickling property (human), 23, 731
 Fenoterol
 binding in heart (human), 24, 174
 nonselective β -adrenergic agonist, binding in heart (human), 24, 169
 Fibroblast
 aryl hydrocarbon hydroxylase induction (mouse), 23, 196
 C3H/10T1/2, cytochrome P-450 induction (mouse), 23, 198
 cultured, adenylate cyclase activity, 23, 648
 pulmonary, prostaglandin synthesis (human), 23, 121
 Flavonoids, effects on splenocyte cell cultures, 23, 698
 Fluorescence, neocarzinostatin chromophore, 23, 500
 Fluorescent probe, in study of drug binding, 24, 458
 5-Fluoro-2'-deoxycytidine, effect on DNA metabolism in HeLa cells, 23, 171
 2-Fluoroestradiol
 carcinogenicity (hamster), 23, 278
 estrogenicity (hamster), 23, 278
 4-Fluoroestradiol
 carcinogenicity (hamster), 23, 278
 estrogenicity (hamster), 23, 278
 5-Fluorouracil
 cellular activity, relationship to folate cofactor pools, 23, 190
 effect on colon carcinoma cells (human), 23, 540

5-Fluorouridine, effect on colon carcinoma cells (human), 23, 540
 Fluphenazine, effect on smooth muscle (bovine), 23, 665
 Flunitrazepam, ³H-labeled, binding sites, solubility (rat), 23, 310
 Folate
 antagonists, of tetrahydrobiopterin, 24, 103
 cellular cofactor pools, 23, 190
 nitrous oxide (rat), 24, 124
 Formate, oxidation (rat), 23, 724
 Forskolin, effect on sperm adenylate cyclase, 24, 42
 Fortimicin, conformation, 23, 127
 Free radical, *p*-aminophenol oxidation, 23, 461

G

Gallamine
 effect on muscarinic receptors (rat), 23, 551
 interaction with muscarinic receptors (rat), 23, 551
 muscarinic receptor induction (rat), 24, 15
 neuromuscular blocking (rat), 24, 15
 Gastric inhibitory polypeptide, effect on 3-*O*-methyl-D-glucose in isolated hepatocytes (rat), 23, 141
 Gelation
 hemoglobin S, 23, 100
 inhibitors, model class, 23, 100
 Gene
 coordinated regulation (rat), 23, 779
 glucocorticoid-inducible, in hepatoma cells (rat), 23, 779
 GH₃ cell
 Ca²⁺-dependent cyclic AMP accumulation (rat), 23, 399
 Ca²⁺ mobilization (rat), 23, 399
 Gland, submaxillary, α_1 -adrenergic receptor turnover (rat), 23, 282
 Glucagon, effect on 3-*O*-methyl-D-glucose in isolated hepatocytes (rat), 23, 141
 Glucocorticoid
 effect on GTP-dependent adenylate cyclase activity, 23, 648
 -inducible genes in hepatoma cells (rat), 23, 779
 response variants (rat), 23, 779
 Glucose metabolism, sorbital pathway, 24, 521
 Glutamate receptor, in hippocampus, 24, 222, 229
 Glutathione, bromobenzene metabolism (rat), 23, 235
 Glycogen
 hepatocytic (rat), 23, 235
 metabolism, cyclic AMP-mediated regulation (*Ascaris*), 23, 378
 synthase, muscle, effect of levamisole (*Ascaris*), 23, 378
 Gonadotropin-releasing hormone, binding to anterior pituitary (rat), 23, 44
 Growth inhibition, by metals, 24, 77
 GTP
 binding protein, caudate nucleus (porcine), 24, 366, 374
 -dependent adenylate cyclase activity, 23, 648
 GTPase
 high-affinity
 effect on adenylate cyclase activity, 24, 380
 in S49 lymphoma *cyc*⁻ and H21a variants, 24, 183
 somatostatin stimulation, 24, 183
 stimulation, 24, 380
 Guanethidine, effects on vas deferens (guinea pig), 23, 409
 Guanine nucleotide(s)
 binding, in adrenal membranes (rat), 23, 369
 effect on angiotensin II receptor (rabbit), 24, 213
 regulatory sites, 24, 183
 synthesis, tiazofurin inhibition, 23, 534
 Guanosine, oxidation (human), 23, 474
 Guanylate cyclase, heme activation (human), 23, 653
 Guanyl nucleotide(s)
 -insensitive sites, binding of [³H]*cis*-methyldioxolane in caudate nucleus (porcine), 24, 374
 regulation of substance P binding in salivary membranes (rat), 23, 563
 salivary gland membrane (rat), 23, 563

-sensitive sites
 binding of [³H]*cis*-methyldioxolane in caudate nucleus (porcine), 24, 374
 [³H]*cis*-methyldioxolane binding to (porcine), 24, 366

H

2'-Halogeno-2'-deoxyuridines, interaction with erythrocyte nucleoside transport mechanism (human), 23, 146
 Halogenonucleosides, interaction with deoxyuridines (human), 23, 146
 Halothane
 chronotropic response, 23, 417
 effect
 on beating in heart cells in culture, 23, 417
 on secretion of liver proteins (rat), 24, 277
 on synthesis of liver proteins (rat), 24, 277
 inotropic response, 23, 417
 Harmala alkaloid, ionization, 23, 614
 Heart
 atrium, phosphatidylinositol metabolism (mouse), 24, 351
 auricles, β -adrenergic receptors (human), 24, 169, 174
 β -adrenergic receptors (rat), 24, 174
 cells
 in culture, effect of calcium on beating, 23, 417
 in culture, effect of halothane on beating, 23, 417
 muscarinic receptors (rat), 24, 15
 HeLa cell
 DNA metabolism, 23, 171
 S₃
 nucleus, chromatin, 23, 493
 nucleus, effects of auromycin, 24, 97
 Heme
 activation of guanylate cyclase (human), 23, 653
 dependency, guanylate cyclase activation (human), 23, 653
 stimulation of cyclic GMP (human), 23, 653
 Hemoglobin
 covalent binding of 4-dimethylaminophenol (human), 24, 282
 sickle, solubility, 23, 100
 Hemoproteins, effect on platelet aggregation (human), 23, 653
 Hepatocyte, isolated
 3-*O*-methyl-D-glucose uptake (rat), 23, 141
 monooxygenase activity (rat), 23, 235
 Hepatoma cell
 variant, glucocorticoid-inducible gene (rat), 23, 779
 wild-type, glucocorticoid-inducible gene (rat), 23, 779
 Hepatotoxicity, *see also* Toxicity
 cocaine (mouse), 23, 482
 Herpes simplex virus
 -infected cells, 24, 90
 mutants, 24, 316
 thymidine kinase, 24, 316
 thymidylate kinase, 24, 316
 Heterogeneity
 benzodiazepine receptor interactions with γ -aminobutyric acid and barbiturate receptor sites (rat), 23, 315
 β -adrenergic receptor binding sites in heart (human), 24, 169, 174
 cardiac muscarinic receptors (rat), 24, 15
 nucleoside transport, in mammalian cells, 24, 479
 site-site interactions (rat), 24, 357
 Hexachlorobiphenyl, metabolism, role of adipose tissue (mouse), 24, 464
 3,4,5,3',4',5'-Hexachlorobiphenyl, induction of cytochrome P-448 (rat), 23, 252
 Hexachloro-1:3-butadiene
 destruction of cytochrome P-450-dependent monooxygenases (mouse, rat), 23, 206
 renal necrosis (mouse, rat), 23, 206
n-Hexane, metabolism, 2,5-hexanedione, 23, 265
 Hippocampus
 acidic amino acid receptors, 24, 222, 229

Hippocampus—Continued

- neurotransmitters, 24, 222
- presynaptic receptors, 24, 229
- Holoantibiotic, chromophore, 24, 97
- Homogenate, urinary bladder, divalent ion-specific binding of ^3H -ATP (rabbit), 23, 1
- Hormone
 - effect on 3-*O*-methyl-D-glucose uptake in isolated hepatocytes (rat), 23, 141
 - gonadotropin-releasing, binding to anterior pituitary (rat), 23, 44
 - responsiveness, role of cyclic AMP, 23, 384
 - steroid, action (rat), 23, 779
- Horseradish peroxidase
 - benzidine activation, 23, 766
 - catalysis of *p*-aminophenol oxidation, 23, 461
- Hydrocarbon, polycyclic aromatic, hepatic metabolism (rat), 24, 115
- Hydrogen, bonding interaction, diphenylhydantoin-9-ethyladenine complex, 23, 273
- Hydrogen peroxide
 - benzphetamine-induced (rat), 23, 748
 - formation by hepatic microsomes (rat), 23, 748
- Hydroquinone, formation, in liver (rat), 23, 453
- N*-Hydroxyamphetamine, microsomal metabolism (rat), 23, 748
- Hydroxybenzylpindolol, ^{125}I -labeled, binding in heart (human), 24, 169
- Hydroxylation
 - biphenyl, K_m and V_{max} (rat), 24, 137
 - tyrosine, tetrahydrobiopterin as cofactor (bovine), 23, 104
- 4-Hydroxylation, debrisoquine (human), 23, 474
- p*-Hydroxylation
 - aniline, inhibitory activity of alcohols, 23, 213
 - microsomal, 23, 213
- Hyperplasia
 - effect on cyclic AMP-dependent protein kinases (rat), 23, 641
 - effect on polyamine enzymes (rat), 23, 641
 - thyroid, effect on enzymes (rat), 23, 641
- Hypertrophy
 - effect on cyclic AMP-dependent protein kinases (rat), 23, 641
 - effect on polyamine enzymes (rat), 23, 641
 - thyroid, effect on enzymes (rat), 23, 641
- Hypophysectomy, effect on thyroid metabolism (rat), 23, 641

I

Ileum

- isolated, muscarinic receptors (guinea pig), 23, 17
- substance P, dissociation constant (guinea pig), 23, 558
- 2-Imidazolines, identification as anti-sickling agents (human), 23, 731
- Imipramine, ^3H -labeled, binding sites, 23, 607
- IMP dehydrogenase, tiazofurin inhibition, 23, 534
- Inactivation, enzyme, cytochrome P-450 (rat), 23, 445
- Induction, drug-metabolizing enzymes (rabbit), 23, 244
- Inhibition
 - acetylcholine transport (ray), 24, 55
 - adenylate cyclase activity, 24, 380
 - adrenal steroidogenesis, 23, 743
 - brain microtubule assembly, by stypoldione (bovine), 24, 493
 - calcium pump, ouabain (bovine), 23, 681
 - cell division (sea urchin), 24, 500
 - competitive
 - cholesterol cleavage, 23, 743
 - drug oxidation (human), 23, 474
 - cytochrome P-450, by chloramphenicol (rat), 23, 445
 - cytochrome P-450_{acc}, 23, 743
 - gelation, model class, 23, 100
 - growth, by metals, 24, 77
 - guanine nucleotide, by tiazofurin, 23, 534
 - IMP dehydrogenase, by tiazofurin, 23, 534
 - kinetics, 23, 717
 - lymphocyte mitogens, by cyclosporin A, 23, 703
 - metabolism, pituitary GH₃ cells, 24, 189
 - 3-*O*-methyl-D-glucose uptake in isolated hepatocytes (rat), 23, 141
 - multiple, kinetics, 24, 30
 - Na^+ - Ca^{2+} exchange in brain (rat), 24, 251
 - noncompetitive, drug oxidation (human), 23, 474
 - nucleoside transport, mecuribenzenesulfonate, 24, 479
 - platelet aggregation, by *S*-nitrosothiols (human), 23, 653
 - pregnenolone synthesis, 23, 743
 - product, tyrosine hydroxylase (bovine), 23, 104
 - sodium pump, ouabain (bovine), 23, 681
 - specific, phosphorylation, 24, 90
 - summation of effects, 24, 30
 - zinc, in hepatic microsomes (rat), 23, 467
- Inhibitor
 - aldose reductase, design, 24, 521
 - calmodulin, interaction with calcium channel blockers, 24, 6
 - cholinesterase, structure-activity relationships, 24, 436
 - dihydrofolate reductase, 24, 103
 - endogenous, competition with benzodiazepines *in vivo* (rat), 23, 310
 - full and partial, interaction on single enzyme, 24, 30
 - methylation, 24, 471
 - phosphodiesterase, effects on sodium nitroprusside and isoproterenol (bovine), 23, 424
 - phospholipase A₂, effect on adrenal medullary cells (bovine), 23, 547
 - site, aldose reductase, pharmacophor requirements, 24, 521
- Insulin, effect on 3-*O*-methyl-D-glucose in isolated hepatocytes (rat), 23, 141
- Interaction
 - drug-membrane, 24, 259
 - nonspecific, structural site, 24, 259
 - site-site (rat), 24, 357
- Intestine
 - epithelial cells, α_2 -adrenergic receptor (rat), 23, 228
 - secretion (rat), 23, 228
- Iododeoxyuridine
 - cytotoxicity, 23, 709
 - metabolism, 23, 709
- Ion
 - divalent
 - ^3H -ATP binding (rabbit), 23, 1
 - ATPase activity (rabbit), 23, 1
 - flux
 - adrenal medullary cells (bovine), 23, 671
 - in adrenal medullary cells (bovine), 23, 681
 - nickel, effect on [^3H]cis-methyldioxolane binding to guanyl nucleotide-sensitive sites (porcine), 24, 366
 - recognition sites, brain-specific (rat), 23, 326
 - requirements for cellular stimulation (bovine), 23, 671
 - tetramethylammonium, electron distribution, 24, 443
- Ionization, harmala alkaloids, 23, 614
- Ionophore-receptor complex, group-selective reagent modification, 23, 52
- Iron-complexing agents, 23, 698
- Isobutacramol, conformational properties, 24, 243
- Isoenzyme, cytochrome P-450
 - induction and aging (rabbit), 23, 244
 - phenobarbital induction (rat), 23, 265
 - xylene induction (rat), 23, 265
- Isoproterenol
 - N*-alkyl-functionalized carboxylic acid congeners and amides, 24, 429
 - effects on coronary artery cells (bovine), 23, 424
 - nonselective β -adrenergic agonist binding in heart (human), 24, 169
 - potentiation (bovine), 23, 424
- Isozyme
 - cytochrome P-450, 23, 748
 - cytochrome P-450 (rabbit), 24, 156
 - hepatic, cytochrome P-450 (rat), 23, 748

K

- Kassinin, dissociation constants in ileum (guinea pig), 23, 558
- 22-Ketocholesterol
inhibition of cholesterol cleavage, 23, 743
kinetics of inhibition, 23, 743
- Kidney
cytochrome P-450 (mouse, rat), 23, 206
hexachloro-1,3-butadiene, cytochrome P-450 destruction (mouse, rat), 23, 206
monoamine oxidase (human), 24, 60
- Kinase
myosin chain, in smooth muscle (bovine), 23, 665
myosin light chain, in tracheal smooth muscle, 24, 235
protein
alteration (rat), 23, 641
cyclic-AMP-dependent, 24, 235
thymidine
herpes simplex virus, 24, 316
substrate specificity, 24, 316
thymidylate, herpes simplex virus, 24, 316
- Kinetics
multiple inhibition, 24, 30
steady-state, tyrosine hydroxylase (bovine), 23, 104

L

- Lactoperoxidase, benzidine activation, 23, 766
- Leiurus quinquestriatus*, venom neurotoxins, 23, 519
- Leukemia
CCRF-CFM cells, drug binding (human), 24, 485
inhibition by 2'-deoxycytidine analogues, 23, 175
L1210 cells, inhibition by nucleoside analogues, 23, 175
- Levamisole, effect on muscle contraction and glycogen metabolism (*Ascaris*), 23, 378
- Ligand
-receptor binding interactions (bovine), 23, 585
stimulatory, interaction with 2',5'-dideoxyadenosine, 24, 195
- Lipid
bilayer, solvation, 24, 259
vesicles, ionic permeability, 24, 270
- Lipoprotein, low-density, estrogen action (rat), 24, 69
- Liver
benzo[*a*]pyrene clearance (rat), 24, 300
biphenyl hydroxylation (rat), 24, 137
cysteine conjugate β -lyase (rat), 23, 761
cytochrome P-450
forms 2, 4, and 5 (rabbit), 24, 156
form 5 (rabbit), 24, 156
form 5, effect of β -naphthoflavone (rabbit), 24, 163
induction by phenobarbital (rat), 23, 265
isoenzyme, induction by xylene (rat), 23, 265
suicide inactivation (rat), 23, 445
daunorubicin-binding protein (rat), 24, 336
dextromethorphan binding (guinea pig), 23, 629
mtDNA polymerase (mouse), 24, 329
effect of halothane (rat), 24, 277
estrogen responsiveness (rat), 24, 69
3-methylcholanthrene treatment (guinea pig), 23, 258
microsome
activation of oxidation (rat), 24, 137
benzphetamine oxidation (rat), 23, 748
biphenyl 2-hydroxylation (rat), 24, 137
cytochrome P-448 (rat), 23, 252
cytochrome P-450 (guinea pig), 23, 258
cytochrome P-450, high-spin form (rat), 24, 146
drug-metabolizing enzymes (rabbit), 23, 244
hydrogen peroxide formation (rat), 23, 748
metabolism of thioacetamide *S*-oxide (rat), 23, 219

- metabolism of *trans*-1,2-dihydroxy-1,2-dihydrobenzo[*a*]anthracene (rat), 24, 115
mixed-function oxidases (rat), 24, 129
NADPH oxidation (rat), 23, 467
phenol metabolism (rat), 23, 453
monoamine oxidase (human), 24, 60
proteins
effect of halothane (rat), 24, 277
secretion (rat), 24, 277
- Location, neutron diffraction, direct determination model, 24, 259
- Loxapine, conformational properties, 24, 243
- Lung
benzo[*a*]pyrene clearance (rat), 24, 300
fibroblasts, prostaglandin synthesis (human), 23, 121
monoamine oxidase (human), 24, 60
- β -Lyase, cysteine conjugate (rat), 23, 761
- Lymphoblast
nucleoside kinase-deficient (human), 23, 153
transport, uridine analogues (human), 23, 153
- Lymphoblastoid cell, transport of uridine and 6-azauridine (human), 23, 153
- Lymphocyte
cyclosporin A sensitivity, 23, 703
interaction with metal-complexing compounds, 23, 698
mitogenic stimulation, 23, 698
mitogens, 23, 703
mitogen-stimulated (mouse), 23, 165
splenic, 2'-deoxycoformycin toxicity (mouse), 23, 165
- Lymphoid cell line
inhibition of proliferation, 23, 698
interaction with metal-complexing compounds, 23, 698
- Lymphoma cell, *cyc*⁻ and H21a variants, 24, 183

M

- Macromolecule, *Schistosoma mansoni*, drug binding, 24, 291
- Macrophage, peritoneal, effect of calmodulin on Ca²⁺ uptake (guinea pig), 23, 78
- Magnesium ion, role in adenylate cyclase activation (rat), 23, 369
- Malaria, intraerythrocytic, anion transport blockers, 23, 92
- Mammary tumor, virus induction (mouse), 23, 779
- Marine products, natural (sea urchin), 24, 500
- Membrane
adrenal, guanine nucleotide binding (rat), 23, 369
anterior pituitary, gonadotropin-releasing hormone binding (rat), 23, 44
biological
effect of electric charge, 24, 270
interaction with propranolol and timolol, 24, 259
cerebellar (rabbit), 24, 23
-drug interactions, 24, 259
erythrocyte, protein, effect of chlorpromazine (human), 23, 771
lipidic model, effect of electric charge, 24, 270
model, interaction with propranolol and timolol, 24, 259
potential, cerebral cortex (guinea pig), 23, 350
S49 lymphoma *cyc*⁻ and H21a variants, high-affinity GTPase, 24, 183
salivary gland, substance P binding (rat), 23, 563
sarcolemmal reticulum, 24, 259
synaptic
cholesterol content (mouse), 23, 86
striatal, adenylate cyclase activity (rat), 23, 393
striatal, muscarinic receptors (rat), 24, 380
synaptosomal, effect of chronic ethanol treatment (mouse), 23, 86
thalamic (rabbit), 24, 23
transport (human), 23, 146
- Mepyramine, ³H-labeled
binding to histamine H₁ receptor, 23, 60
temperature dependence of binding, 23, 60
- Mercaptan-stimulated DNA scission activity, 23, 500

- Mercuribenzenesulfonate, inhibition of nucleoside transport, **24**, 479
- Mercury, growth inhibition, **24**, 77
- Mercury (II), cell survival after exposure, **24**, 84
- Metabolic clearance rate, methodology, for circulating proteins (rat), **23**, 112
- Metabolism
- adrenal medullary cells (bovine), **23**, 671
 - aromatic amines, in liver (rabbit), **24**, 156
 - benzo[*a*]pyrene, **23**, 735
 - benzo[*a*]pyrene (rat), **24**, 300
 - product inhibition, **23**, 735
 - bromobenzene, glutathione (rat), **23**, 235
 - Ca²⁺, in pituitary tumor cells (rat), **23**, 399
 - cyclic AMP, muscarinic cholinergic receptor-mediated, **23**, 384
 - drug
 - hepatic microsomal enzymes (rabbit), **23**, 244
 - reductive (schistosoma), **24**, 291
 - DNA, in HeLa cells, **23**, 171
 - glucose, sorbitol pathway, **24**, 521
 - glycogen, cyclic AMP-mediated regulation (*Ascaris*), **23**, 378
 - hexachlorobiphenyl, role of adipose tissue (mouse), **24**, 464
 - iododeoxyuridine, **23**, 709
 - microsomal (rat), **24**, 300
 - phenol, hepatic microsome (rat), **23**, 453
 - phosphatidylinositol, in heart (mouse), **24**, 351
 - phosphoinositide, in parotid gland (rat), **23**, 71
 - pituitary GH₃ cells, **24**, 189
 - reductive, niridazole (schistosoma), **24**, 291
 - requirements for cellular stimulation (bovine), **23**, 671
 - stereoselective, polycyclic aromatic hydrocarbons (rat), **24**, 115
 - thioacetamide *S*-oxide (rat), **23**, 219
 - thyroid, effect of hypophysectomy (rat), **23**, 641
 - tiazofurin, **23**, 534
 - trans*-1,2-dihydroxy-1,2-dihydrobenz[*a*]anthracene (rat), **24**, 115
- Metabolite, 3-methylcholanthrene (mouse), **23**, 198
- Metal
- complexation, with rifamycins, **23**, 133
 - complexing agents, **23**, 698
 - complexing compounds, cellular interaction, **23**, 698
 - essential
 - cadmium induction, **24**, 77
 - growth inhibition, **24**, 77
 - non-essential
 - cadmium induction, **24**, 77
 - growth inhibition, **24**, 77
- Metallithionin, induction by metals, **24**, 77
- Metamphetamine, microsomal metabolism (rat), **23**, 748
- Methanol poisoning (rat), **23**, 724
- Methionine
- effect on hepatic *S*-adenosylmethionine (rat), **24**, 124
 - effect on hepatic methylation reactions (rat), **24**, 124
 - nitrous oxide (rat), **24**, 124
 - synthetase
 - hepatic, effects of methotrexate (rat), **23**, 724
 - hepatic, effects of nitrous oxide (rat), **23**, 724
- Methotrexate, effects on liver (rat), **23**, 724
- 3-Methoxy-4-aminoazobenzene, cytochrome P-450 induction (rat), **24**, 146
- Methylation
- nitrous oxide (rat), **24**, 124
 - phospholipid, nitrous oxide (rat), **24**, 124
 - thiol, **24**, 471
- N*-Methylcarbazole, *N*-demethylation, **23**, 758
- 3-Methylcholanthrene
- effect on hepatocytic monooxygenase activity (rat), **23**, 235
 - induction of cytochrome P-448 (rat), **23**, 252
 - induction of cytochrome P-450 in fibroblasts (mouse), **23**, 198
- cis*-Methyldioxolane, ³H-labeled
- binding in caudate nucleus (porcine), **24**, 374
 - binding to guanyl nucleotide-sensitive sites (porcine), **24**, 366
- Methylene blue, effect in vas deferens (guinea pig), **23**, 409
- Methylenedioxybenzene, derivatives, hepatic microsomal (rat), **24**, 129
- 3-*O*-Methyl-D-glucose, uptake in isolated hepatocytes (rat), **23**, 141
- N*-Methyl-*N*-(1-methyl-4-pyrrolidino-2-butynyl)acetamide, action at muscarinic cholinergic synapses, **24**, 1
- N*-Methyl-4-piperidyl benzilate, binding in adenohipophysis (rat), **24**, 357
- Methyltransferase, thiopurine
- action, **24**, 471
 - effect of benzoic acid derivatives, **24**, 471
- Metoprolol, binding in heart (human), **24**, 169, 174
- Microsome
- benzo[*a*]pyrene metabolism, **23**, 735
 - brain, high-affinity dextromethorphan binding sites (guinea pig), **23**, 619
 - hepatic
 - activation of oxidation (rat), **24**, 137
 - benzphetamine oxidation (rat), **23**, 748
 - biphenyl 2-hydroxylation (rat), **24**, 137
 - cytochrome P-448 (rat), **23**, 252
 - cytochrome P-450 (guinea pig), **23**, 258
 - drug-metabolizing enzymes (rabbit), **23**, 244
 - high-spin form of cytochrome P-450 (rat), **24**, 146
 - hydrogen peroxide formation (rat), **23**, 748
 - metabolism of thioacetamide *S*-oxide (rat), **23**, 219
 - metabolism of *trans*-1,2-dihydroxy-1,2-dihydrobenz[*a*]anthracene (rat), **24**, 115
 - mixed-function oxidases (rat), **24**, 129
 - monooxygenase activity (rat), **23**, 467
 - NADPH oxidation (rat), **23**, 467
 - phenol metabolism (rat), **23**, 453
 - p*-hydroxylation, **23**, 213
 - metabolism (rat), **24**, 300
- Microtubule, brain, assembly, inhibition by stypoldione (bovine), **24**, 493
- Microvessel, cerebral
- α*pha₁-adrenergic receptor (dog), **24**, 163
 - phosphatidylinositol effect (dog), **24**, 163
- Mitochondria, hepatic, DNA polymerase (mouse), **24**, 329
- Mitogen, lymphocyte, **23**, 703
- stimulation, **23**, 698
 - stimulation (mouse), **23**, 165
- Mitogenesis, sensitivity to cyclosporin A, **23**, 703
- Mitosis, anti-, drugs, **24**, 324
- Molecular mass, relative, characteristics, **23**, 258
- Molecular mechanics, calculations, **24**, 243
- Molecular orbital calculation, electron distribution in tetramethylammonium ion, **24**, 443
- Molecular size, D₂-dopamine receptor (dog, human), **24**, 10
- Molecular structure, sodium rifamycin SV, **23**, 133
- Molecular topology, steric parameters, **23**, 213
- Monoacetylbenzidine, activation by peroxidases, **23**, 766
- Monoamine oxidase
- brain (human), **24**, 60
 - kidney (human), **24**, 60
 - liver (human), **24**, 60
 - lung (human), **24**, 60
 - radioimmunoassay (human), **24**, 60
- Monoclonal antibodies, cholinesterases (human), **24**, 513
- Monooxygenase
- activity
 - in hepatic microsomes (rat), **23**, 467
 - in isolated hepatocytes (rat), **23**, 235
 - betamethasone activation (rat), **24**, 137
 - cytochrome P-450-dependent, destruction (mouse, rat), **23**, 206
 - FAD-containing, *N*-demethylation of cocaine (mouse), **23**, 482
 - steroid activation (rat), **24**, 137
- Muscarinic receptor

- acetylcholine, binding in caudate nucleus (porcine), 24, 366
 action, 24, 1
 agonist, inhibition of adenylate cyclase activity (rat), 23, 398
 binding properties (rat), 23, 551
 cardiac, heterogeneity (rat), 24, 15
 effect on phosphatidylinositol metabolism in heart (mouse), 24, 351
 gallamine inhibition (rat), 23, 551
 heart selectivity (rat), 23, 551
 ileal, oxotremorine analogues (guinea pig), 23, 17
 in caudate nucleus (porcine), 24, 366, 374
 modification of binding by gallamine (rat), 23, 551
 second binding site (rat), 23, 551
 striatal, coupling to adenylate cyclase, 24, 380
- Muscle**
 BC3H-1 clonal cell, 23, 8
 contraction, effect of levamisole (*Ascaris*), 23, 378
 L6 cells
 intact, 24, 398
 interactions of full and partial agonists with *beta*-adrenergic receptors, 24, 398
 levamisole-perfused, cyclic AMP-mediated regulation of glycogen metabolism (*Ascaris*), 23, 378
 smooth
alpha-adrenergic contraction (dog), 23, 570
 contraction (bovine), 23, 665
 contraction (rat), 23, 359
 effects of fluphenazine (bovine), 23, 665
 tracheal, *alpha*-adrenergic receptors (dog), 23, 570
 urinary bladder (rabbit), 23, 1
- Mutagenesis**
 2-aminoanthracene (rabbit), 24, 156
 2-aminofluorene (rabbit), 24, 156
 aromatic amine-induced (rabbit), 24, 156
 phenobarbital induction (rabbit), 24, 156
- Mutant, herpes simplex virus**, 24, 316
- Myocardium, cell membrane, calcium uptake and release**, 23, 417
- Myosin**
 light chain kinase
 in smooth muscle (bovine), 23, 665
 in tracheal smooth muscle, 24, 235
 phosphorylation
 in smooth muscle (bovine), 23, 665
 in tracheal smooth muscle, 24, 235
- Myocardium, ventricular receptor for angiotensin II** (rabbit), 24, 213
- N**
- ²²Na⁺, permeability, carbamylcholine-stimulated, 23, 8
 Na⁺
 -Ca²⁺, exchange in brain (rat), 24, 251
 transport in brain (rat), 24, 251
- NAD, analogue formation**, 23, 534
- NADPH oxidation, effect of zinc** (rat), 23, 467
- Naloxone, dynorphin antagonism**, 23, 36
- β -Naphthoflavone, effect on hepatic cytochrome P-450, form 5** (rabbit), 24, 156
- Naphthoic acid, moiety**, 23, 500
- Neocarcinostatin**
 circular dichroism, 23, 500
 chromophore, binding to DNA, 23, 500
 degradation of chromatin, 23, 493
 effects on chromatin in HeLa S₃ nuclei, 23, 493
 fluorescence, 23, 500
- Neuroblastoma, *delta*-subtype opiate receptors**, 24, 413
- Neuroblastoma cell, \times glioma NG108-15 hybrid, opiate regulation of cyclic AMP levels**, 23, 26
- Neuroleptic**
 conformational properties, 24, 243
 receptor (dog, human), 24, 10
 semirigid, 24, 243
- Neuromuscular blocking**
 gallamine (rat), 24, 15
 pancuronium (rat), 24, 15
- Neuron**
 acetylcholine-activated channels, barbiturate effects, 24, 449
 adrenergic, effects of guanethidine (guinea pig), 23, 409
 serotonergic, association with cocaine binding (mouse, rat), 23, 600
 serotonin uptake, 23, 607
- Neurotoxicity**
 esterase (chicken), 23, 717
 organophosphorus compounds (chicken), 23, 717
- Neurotoxin**
 polypeptide, 23, 519
 scorpion, purification and physiology, 23, 519
- Neurotransmitter**
 in hippocampus, 24, 222
 receptor
 structure (dog, human), 24, 10
 target size (dog, human), 24, 10
- Neurotumor cell, NCB-20 hybrid, ethylketocyclazocine binding**, 23, 486
- Neutron diffraction, location, direct determination method**, 24, 259
- Nickel**
 growth inhibition, 24, 77
 ion, effect on [³H]*cis*-methyldioxolane binding to guanyl nucleotide-sensitive sites (porcine), 24, 366
- Nicotinic acetylcholine receptor, effect of semirigid agonists** (frog), 23, 337
- Niridazole**
 antiparasitic activity (schistosome), 24, 291
 reductive metabolism (schistosome), 24, 291
- Nitrobenzylthioinosine, effect on nucleoside transport in cultured mammalian cells**, 24, 479
- Nitrogen**
 oxide, effect on platelet aggregation (human), 23, 653
 -steroid mustard, cytotoxicity, 24, 324
- Nitroreductase, schistosome**, 24, 291
- Nitroreduction (schistosome)**, 24, 291
- Nitrothiazole derivative**, 24, 291
- 2-Nitroso-1-phenylpropane, microsomal metabolism** (rat), 23, 748
- S-Nitrosothiols, inhibition of platelet aggregation** (human), 23, 653
- Nitrous oxide**
 effect on hepatic *S*-adenosylmethionine (rat), 24, 124
 effect on hepatic methylation reactions (rat), 24, 124
 effects on liver (rat), 23, 724
 folates (rat), 24, 124
 toxicity (rat), 24, 124
- Norbenzphetamine, microsomal metabolism** (rat), 23, 748
- Norcocaine, cocaine *N*-demethylation** (mouse), 23, 482
- Norepinephrine, effect on vas deferens** (rat), 23, 359
- Noscapine, effect on dextromethorphan binding**, 23, 629
- Nuclear matrix, estramustine binding**, 24, 324
- Nuclear Overhauser enhancement, conformation of fortimicins**, 23, 127
- Nucleic acid, in colon carcinoma cells in culture** (human), 24, 309
- Nucleoside**
 erythrocyte transport mechanism, interaction with 2'-halogeno-2'-deoxyuridines (human), 23, 146
 kinase-deficient lymphoblasts (human), 23, 153
 transport (human), 23, 146
 heterogeneity in mammalian cells, 24, 479
 in cultured mammalian cells, 24, 479
- Nucleosome, degradation**, 24, 97
- Nucleotide**
 degradation, agonist-induced changes, 23, 384
 guanine
 effect on angiotensin II receptor (rabbit), 24, 213
 regulatory sites, 24, 183
 tiazofurin inhibition, 23, 534

Nucleotide—*Continued*

- guanyl
 - regulation of substance P binding in salivary membranes (rat), 23, 563
 - salivary gland membrane (rat), 23, 563
- regulatory protein (rat), 24, 341
- sensitivity for *beta*-adrenergic receptors (rat), 24, 341
- synthesis, agonist-induced changes, 23, 384

Nucleus

- HeLa S₃ cell
 - chromatin, 23, 493
 - effects of auromomycin, 24, 97
- soluble chromatin, 24, 97

O

Octoclotheptin, conformational properties, 24, 243

Opiate

- multiple binding sites in central nervous system (rabbit), 24, 23
- receptor
 - delta*-subtype, in neuroblastomas, 24, 413
 - desensitization in neuroblastoma × glioma NG108-15 hybrid cells, 24, 413
 - down-regulation in neuroblastoma × glioma NG108-15 hybrid cells, 24, 413
 - in neuroblastoma × glioma NG108-15 hybrid cells, 23, 26
 - mu* and *kappa* subtypes from brain (rat), 24, 203
- regulation, cellular cyclic AMP, 23, 26

Opioid receptor, *kappa*, 23, 36

Organophosphorus compounds, neurotoxicity (chicken), 23, 717

Ornithine decarboxylase, thyroid (rat), 23, 641

Ouabain

- calcium pump inhibition (bovine), 23, 681
- effect on adrenal medullary cells (bovine), 23, 681
- sodium pump inhibition (bovine), 23, 681
- stimulated secretion in adrenal medullary cells (bovine), 23, 671

Oxidase, mixed-function, microsomal (rat), 24, 129

Oxidation

- p*-aminophenol, catalysis, 23, 461
- formate (rat), 23, 724
- NADPH
 - effect of zinc (rat), 23, 467
 - in hepatic microsomes (rat), 23, 467
- sequential, benzphetamine (rat), 23, 748

N-Oxidation

- cytochrome P-450 (mouse), 23, 482
- FAD-containing monooxygenase (mouse), 23, 482

Oxotremorine analogue(s), 24, 1

- ileal muscarinic receptors (guinea pig), 23, 17

Oxygen atom, source in *N*-demethylation reactions, 23, 758

Oxygen 18 incorporation (rat), 23, 219

P

Pancreozymin, effect on 3-*O*-methyl-D-glucose in isolated hepatocytes (rat), 23, 141

Pancuronium

- muscarinic receptor induction (rat), 24, 15
- neuromuscular blocking (rat), 24, 15

Paralysis, role of cyclic AMP-mediated glycogen metabolism (*Ascaris*), 23, 378Parasite, *Schistosoma mansoni*, macromolecular drug binding, 24, 291

Parotid gland

- calcium mobilization (rat), 23, 71
- phosphatidic acid synthesis (rat), 23, 71
- phosphoinositide metabolism (rat), 23, 71

Peptide, vasoactive intestinal

- epithelial (rat), 23, 228
- modulation of adenylate cyclase in pituitary GH₃ cells, 24, 189
- modulation of cyclic AMP content in pituitary GH₃ cells, 24, 189
- modulation of prolactin secretion in pituitary GH₃ cells, 24, 189

Percoll density gradient, separation of parenchymal cells (rat), 23, 235

Permeability, ²²Na⁺, carbamylcholine-stimulated, 23, 8

Peroxidase

- benzidine activation, 23, 766
- horseradish, benzidine activation, 23, 766
- lactoperoxidase, benzidine activation, 23, 766

pH-dependent transport, in lymphoblastoid cells (human), 23, 153

Pharmacokinetics, liver and lung (rat), 24, 300

Pharmacology, light-flash (eel), 23, 344

Pharmacophor requirements of aldose reductase inhibitor site, 24, 521

Phencyclidine, inhibition of ethylketocyclazocine binding, 23, 486

Phenformin, oxidation (human), 23, 474

Phenobarbital

- effect of long-term administration on hepatic mtDNA polymerase (mouse), 24, 329
- effect on benzphetamine oxidation (rat), 23, 748
- effect on hepatic aromatic amines (rabbit), 24, 156
- effect on hepatic cytochrome P-450 forms (rabbit), 24, 156
- effect on hepatic microsomes (rat), 23, 748
- effect on hepatocytic monooxygenase activity (rat), 23, 235
- hepatic centrilobular hypertrophy after long-term treatment (mouse), 24, 329

induction of cytochrome P-450 isozyme (rat), 23, 265

mutagenesis induction (rabbit), 24, 156

Phenol, biotransformation, by liver microsomes (rat), 23, 453

Phenothiazine, effect on dextromethorphan binding, 23, 629

Phenylalanine derivatives, effect on deoxyhemoglobin S, 23, 100

Phenyl *N*-methyl carbamates, affinities, quantum mechanical study, 24, 436

2-(4-Phenylpiperidino)cyclohexanol, effect on acetylcholine transport (ray), 24, 48

Phorbol esters, tumor-promoting, 23, 703

Phosphatidic acid, synthesis in parotid gland (rat), 23, 71

Phosphatidylinositol

- effect in cerebral microvessels (dog), 24, 163

metabolism in heart (mouse), 24, 351

Phosphodiesterase inhibitors

- effects on coronary artery cells (bovine), 23, 424
- effects on sodium nitroprusside and isoproterenol (bovine), 23, 424

Phosphoinositide

- metabolism in heart (mouse), 24, 351
- metabolism in parotid gland (rat), 23, 71

Phospholipase A₂ inhibitors, effect on adrenal medullary cells (bovine), 23, 547

Phospholipid, methylation, nitrous oxide (rat), 24, 124

Phosphorylase

- muscle, effect of levamisole (*Ascaris*), 23, 378
- smooth muscle (bovine), 23, 665

Phosphorylation

- myosin
 - in smooth muscle (bovine), 23, 665
 - in tracheal smooth muscle, 24, 235
- 5-trifluoromethyl-2'-deoxyuridine, 24, 90

Physalaemin, dissociation constants in ileum (guinea pig), 23, 558

Physical dependence, ethanol (mouse), 23, 86

Physical state, lipid bilayer properties, drug solvation, 24, 259

Physiology, scorpion neurotoxins, 23, 519

Picrotoxin receptor, brain-specific binding (rat), 23, 326

Picrotoxinin receptor, computer-assisted modeling, 23, 511

Pindolol, binding in heart (human), 24, 169

Pituitary

anterior

- adenylate cyclase (rat), 23, 576
- D-2 dopamine receptor (bovine), 23, 585
- D₂ dopamine receptor (rat), 23, 576
- gonadotropin-releasing hormone binding (rat), 23, 44
- intact cells (bovine), 23, 295

GH₃ cells

- adenylate cyclase, 24, 189

cyclic AMP content, **24**, 189
 prolactin secretion, **24**, 189
 neurointermediate lobe, [³H]prazosin-labeled α_1 -receptors (porcine), **24**, 409
 tumor cells
 Ca²⁺-dependent cyclic AMP accumulation (rat), **23**, 399
 Ca²⁺ metabolism (rat), **23**, 399
 pK_a, low, anomalous, **24**, 243
 Plasma, butyrylcholinesterase, monoclonal antibodies (human), **24**, 513
Plasmodium falciparum, growth suppression *in vitro*, **23**, 92
 Platelet
 aggregation, inhibition by S-nitrosothiols (human), **23**, 653
 cocaine binding (human), **23**, 600
 serotonin uptake, **23**, 607
 Poisoning, methanol (rat), **23**, 724
 Polyamine, enzyme alteration (rat), **23**, 641
 Polychlorinated biphenyl
 induction of high-spin form of cytochrome P-450 (rat), **24**, 146
 pharmacokinetics, induction of drug-metabolizing enzymes (mouse), **24**, 464
 Polycyclic aromatic hydrocarbon, hepatic metabolism (rat), **24**, 115
 Polymerase, mtDNA, characterization (mouse), **24**, 329
 Polymorphism, drug oxidation (human), **23**, 474
 Polyol, pathway, **24**, 521
 Polypeptide, neurotoxins, **23**, 519
 Potassium, calcium-activated conductance (guinea pig), **23**, 409
 Potentiation
 isoproterenol effects (bovine), **23**, 424
 sodium nitroprusside effects (bovine), **23**, 424
 P Site, stimulatory ligands, **24**, 195
 Purification
 daunorubicin-binding protein from liver (rat), **24**, 336
 scorpion neurotoxins, **23**, 519
 Pyrazolopyridines, brain-specific binding (rat), **23**, 326
 Practolol binding in heart (human), **24**, 169, 174
 Prazosin, ³H-labeled, α_1 -receptors in pituitary (porcine), **24**, 409
 Pregnenolone synthesis, inhibition, **23**, 743
 Procaterol, binding in heart (human), **24**, 169, 174
 Products, natural, marine (sea urchin), **24**, 500
 Prolactin
 effect on Ca²⁺ metabolism in pituitary tumor cells (rat), **23**, 399
 effect on cyclic AMP accumulation in pituitary tumor cells (rat), **23**, 399
 -modulating hormones, effect on Ca²⁺ and cyclic AMP (rat), **23**, 399
 regulation (rat), **23**, 576
 secretion in pituitary GH₃ cells, **24**, 189
 Propranolol
 binding in heart (human), **24**, 169, 174
 interaction with membranes, **24**, 259
 Propylthiouracil
 -stimulated thyroid hyperplasia (rat), **23**, 641
 -stimulated thyroid hypertrophy (rat), **23**, 641
 Prostaglandin
 E₁, intestinal epithelial (rat), **23**, 228
 synthase, catalysis of *p*-aminophenol oxidation, **23**, 461
 synthesis, effect of cannabinoids (human), **23**, 121
 Protein
 antitumor
 antibiotic, **23**, 500
 effect on HeLa S₃ nuclei, **24**, 97
 carboxymethylation, nitrous oxide (rat), **24**, 124
 circulating, metabolic clearance rate (rat), **23**, 112
 covalent binding (rat), **23**, 219
 daunorubicin-binding, from liver (rat), **24**, 336
 erythrocyte membrane, effect of chlorpromazine (human), **23**, 771
 estrogen-binding (rat), **24**, 69
 kinase
 alteration (rat), **23**, 641
 cyclic AMP-dependent, **24**, 235

liver, effect of halothane (rat), **24**, 277
 nucleotide regulatory (rat), **24**, 341
 secretion, effect of halothane (rat), **24**, 277
 synthesis, in colon carcinoma cells in culture (human), **24**, 309

Q

Quantum mechanics, in study of phenyl *N*-methyl carbamates, **24**, 436
 Quinazolines, conformation for binding, **24**, 425
 Quinine, effect in vas deferens (guinea pig), **23**, 409
 Quinone, intercalation, DNA, **23**, 735
 Quinuclidinyl benzilate, binding in adenohipophysis (rat), **24**, 357

R

Radiation inactivation, in study of dopamine D₂ receptor (dog, human), **24**, 10
 Radical, free, in benzidine oxidation, **23**, 766
 Radioligand, binding in trachea (dog), **23**, 570
 Radioimmunoassay
 double-antibody, identification of hepatic cytochrome P-448, **23**, 252
 monoamine oxidase (human), **24**, 60
 Receptor
 acetylcholine
 effect of *cis*-bis-Q (eel), **23**, 344
 nicotinic, agonist occupation and functional response, **23**, 8
 adenohipophyseal, effect of muscarinic antagonists on conformation (rat), **24**, 357
 adrenergic, *see* Adrenergic receptor
 -agonist, high-affinity states (bovine), **23**, 295
 amino acid, acidic, in hippocampus, **24**, 222, 229
 γ -aminobutyric acid
 -chloride ion channel complex (rat), **23**, 315
 interactions with benzodiazepine receptor (rat), **23**, 315
 barbiturate, interactions with benzodiazepine receptor (rat), **23**, 315
 benzodiazepine
 binding, extraction in distilled water (rat), **23**, 310
 binding kinetics (rat), **23**, 289
 brain-specific (rat), **23**, 326
 conformational change (rat), **23**, 289
 endogenous inhibitor(s), (rat), **23**, 310
 interactions with γ -aminobutyric acid and barbiturate receptor sites (rat), **23**, 315
 ligand interactions, **24**, 425
 subtypes (rat), **23**, 315
 brain antidepressants, **23**, 594
 γ -butyrolactone, computer-assisted modeling, **23**, 511
 complexes in brain (rat), **23**, 326
 divalent cation, salivary gland membrane (rat), **23**, 563
 dopamine
 adenohipophyseal (rat), **23**, 576
 agonist/antagonist interactions (rat), **23**, 303
 binding on intact cells (bovine), **23**, 295
 D₂ (bovine), **23**, 585
 D₂, characterization (rat), **23**, 576
 D₂, molecular size (dog, human), **24**, 10
 in brain (dog, human), **24**, 10
 molecular weight (dog, human), **24**, 10
 thermodynamics (rat), **23**, 303
 dynorphin
 ileum (guinea pig), **23**, 36
 vas deferens (mouse), **23**, 36
 estrogen, hepatic (rat), **24**, 69
 glutamate, in hippocampus, **24**, 222, 229
 histamine H₁, [³H]mepyramine binding, **23**, 60
 -ionophore complex, group-selective reagent modification, **23**, 52
 -ligand binding interactions (bovine), **23**, 585
 low-affinity states, **24**, 398

Receptor—Continued

- multiple binding states (bovine), 23, 585
- multiple opiate, 23, 486
- multiplicity, binding in brain (rat), 23, 326
- muscarinic
 - acetylcholine, binding in caudate nucleus (porcine), 24, 366
 - action, 24, 1
 - adenohypophyseal (rat), 24, 357
 - agonist, inhibition of adenylate cyclase activity (rat), 23, 393
 - binding properties (rat), 23, 551
 - cardiac, heterogeneity (rat), 24, 15
 - cholinergic, effect on cyclic AMP metabolism, 23, 384
 - coupling to adenylate cyclase, 24, 380
 - effect on phosphatidylinositol metabolism in heart (mouse), 24, 351
 - gallamine inhibition (rat), 23, 551
 - heart selectivity (rat), 23, 551
 - ileal, oxotremorine analogues (guinea pig), 23, 17
 - in caudate nucleus (porcine), 24, 366, 374
 - modification of binding by gallamine (rat), 23, 551
 - second binding site (rat), 23, 551
- neuroleptic (dog, human), 24, 10
- neurotransmitter
 - structure (dog, human), 24, 10
 - target size (dog, human), 24, 10
- nicotinic
 - acetylcholine, effect of semirigid agonists (frog), 23, 337
 - cholinergic, in brain (rat), 24, 387
 - chromaffin cell (bovine), 23, 437
- occupancy in vas deferens (rat), 23, 359
- opiate
 - delta*-subtype, in neuroblastomas, 24, 413
 - desensitization in neuroblastoma × glioma NG108-15 hybrid cells, 24, 413
 - down-regulation in neuroblastoma × glioma NG108-15 hybrid cells, 24, 413
 - in neuroblastoma × glioma NG108-15 hybrid cells, 23, 26
 - mu* and *kappa* subtypes from brain (rat), 24, 203
- opioid, *kappa*, 23, 36
- picrotoxin, brain-specific binding (rat), 23, 326
- picrotoxinin, computer-assisted modeling, 23, 511
- presynaptic, in hippocampus, 24, 229
- serotonin, antagonist, 23, 594
- spare
 - dynorphin potency, 23, 36
 - ileal (guinea pig), 23, 17
- substance P
 - in ileum (guinea pig), 23, 558
 - in salivary membranes (rat), 23, 563
 - inactivation with phenoxybenzamine (guinea pig), 23, 558
- 2,3,7,8-tetrachlorodibenzo-*p*-dioxin in fibroblasts (mouse), 23, 198
- translocation, in sex differentiation (rat), 24, 69
- ventricular myocardial, for angiotensin II (rabbit), 24, 213
- Reconstitution, ion exchange, in brain (rat), 24, 251
- Reductase, aldose
 - inhibitor site, pharmacophor requirements, 24, 521
 - inhibitors, design, 24, 521
- Regulation
 - Ca²⁺-dependent cyclic AMP accumulation in pituitary tumor cells (rat), 23, 399
 - cellular cyclic AMP, by opiates, 23, 26
 - genetic, coordinated (rat), 23, 779
 - prolactin (rat), 23, 576
- Regulator
 - deoxycytidylate deaminase, chemotherapeutic implications (human), 23, 159
 - enzymic, action (human), 23, 159
- Relative molecular mass, characteristics, spectrum, 23, 258
- Relaxation, *beta*-adrenergic, in tracheal smooth muscle, 24, 235
- Resistance
 - drug, mechanism (human), 24, 485
 - vinblastine (human), 24, 485
 - Vinca* alkaloid (human), 24, 485
- Reticulocyte, *beta*-adrenergic receptors (rat), 24, 174
- Reticulum, sarcoplasmic, membrane, 24, 259
- 2- β -D-Ribofuranosylthiazole-4-carboxamide, metabolism, 23, 534
- Ribonucleoside, triphosphates, lymphocytic (mouse), 23, 165
- Rifamycin SV, sodium salt, molecular structure, 23, 133
- RNA
 - messenger
 - in vitro* translation (human), 23, 540
 - in vitro* translational activity, 24, 509
 - polyadenylated, sangivamycin incorporation (human), 24, 509
 - synthesis, in lymphocytes (mouse), 23, 165
- Ro 11-2465 binding, 23, 607

S

- Salbutamol, binding in heart (human), 24, 169, 174
- Salivary gland, membranes, substance P binding (rat), 23, 563
- Sangivamycin
 - effect on messenger RNA (human), 24, 509
 - treatment of colon carcinoma cells (human), 24, 509
- Saponin, macrophage treatment (guinea pig), 23, 78
- Sarcoplasmic reticulum, membrane, 24, 259
- Schistosoma mansoni*, reductive metabolism of niridazole, 24, 291
- Schistosoma, nitroreductase, 24, 291
- Scorpion venom
 - binding in cerebral cortex (guinea pig), 23, 350
 - neurotoxins, 23, 519
- Secretion
 - ascorbic acid, chromaffin cells (bovine), 23, 437
 - calcium uptake (bovine), 23, 547
 - catecholamine, adrenal medullary cells (bovine), 23, 547, 671, 681
 - liver proteins, effect of halothane (rat), 24, 277
- Seminal vesicle, microsomes, *p*-aminophenol oxidation, 23, 461
- Sensitivity
 - drug, modified, herpes simplex virus, 24, 316
 - nucleotide, for *beta*-adrenergic receptors (rat), 24, 341
- Serotonin
 - binding (mouse, rat), 23, 600
 - uptake
 - neuronal, 23, 607
 - platelet, 23, 607
 - receptor, antagonist, 23, 594
- Serotonin₁, binding sites, 23, 594
- Sickle cell anemia, 2-imidazoline treatment (human), 23, 731
- Sex differences, translocation receptors (rat), 24, 69
- Sex differentiation, estrogen-binding proteins (rat), 24, 69
- Sodium
 - channel
 - cerebral cortex (guinea pig), 23, 350
 - effect of scorpion neurotoxins, 23, 519
 - efflux assay, acidic amino acid receptors in hippocampus, 24, 222
 - pump, inhibition by ouabain (bovine), 23, 681
- Sodium nitroprusside
 - effects on coronary artery cells (bovine), 23, 424
 - potentiation (bovine), 23, 424
- Solubility
 - deoxyhemoglobin S, 23, 100
 - [³H]flunitrazepam binding sites, effect of diazepam (rat), 23, 310
- Solubilization
 - benzodiazepine binding sites, with distilled water (rat), 23, 310
 - mu* and *kappa* opiate receptor subtypes from brain (rat), 24, 203
- Solvation
 - enzyme inhibition, nonspecific site of interaction, 24, 259
 - lipid bilayer, 24, 259
- Somatostatin

- adenylate cyclase inhibition, 24, 183
 - GTPase stimulation, 24, 183
 - induced stimulation of GTPase, 24, 183
 - Sorbitol pathway, glucose metabolism, 24, 521
 - Sparteine, oxidation (human), 23, 474
 - Specificity, substrate (human), 23, 159
 - 4-hydroxylation of debrisoquine (human), 23, 474
 - Spectral property, neocarzinostatin chromophore, 23, 500
 - Sperm, adenylate cyclase, effect of forskolin, 24, 42
 - Spin label, in study of ethanol tolerance (mouse), 23, 86
 - Spiroperidol, ³H-labeled
 - binding on intact cells (bovine), 23, 295
 - in striatum (rat), 23, 303
 - temperature dependency (rat), 23, 303
 - Spleen, lymphocytes, 2'-deoxycoformycin toxicity (mouse), 23, 165
 - Splenocyte, interaction of metal-complexing compounds, 23, 698
 - Stereoselectivity, oxotremorine analogues, for ileal muscarinic receptors (guinea pig), 23, 17
 - Stereospecificity, gelation inhibitors, 23, 100
 - Steroid
 - activation of monooxygenases (rat), 24, 137
 - glucocorticoid, effect on cultured fibroblasts, 23, 648
 - hormone, action (rat), 23, 779
 - nitrogen mustard, cytotoxicity, 24, 324
 - Steroidogenesis, adrenal, inhibition, 23, 743
 - Stimulation
 - ionic, cellular (bovine), 23, 671
 - metabolic, cellular (bovine), 23, 671
 - metabolism, pituitary GH₃ cells, 24, 189
 - muscarinic, cyclic GMP, 24, 1
 - somatostatin-induced, GTPase, 24, 183
 - Striatum
 - dopamine receptor binding (rat), 23, 303
 - muscarinic receptors, coupling to adenylate cyclase, 24, 380
 - synaptic membranes
 - adenylate cyclase activity (rat), 23, 393
 - muscarinic receptors (rat), 24, 380
 - Structure
 - neocarzinostatin chromophore, 23, 500
 - requirements for drug binding on human serum albumin, 24, 458
 - Structure-activity relationship
 - ansamycins, 23, 133
 - cholinesterase inhibitors, 24, 436
 - 3-dimensional, in aminoglycoside antibiotics, 23, 127
 - human serum albumin site II, 24, 458
 - in interactions of alkoxymethylenedioxybenzene derivatives (rat), 24, 129
 - induction (rat), 24, 129
 - oxotremorine analogues, 23, 17
 - quantitative
 - enzyme inhibition, 23, 213
 - study, inhibition of microsomal *p*-hydroxylation, 23, 213
 - Stypoldione
 - effect on embryonic cell cycle progression (sea urchin), 24, 500
 - effect on embryonic cell division (sea urchin), 24, 500
 - effect on embryonic DNA and protein synthesis (sea urchin), 24, 500
 - inhibition of brain microtubule assembly (bovine), 24, 493
 - Submaxillary gland, α ₁-adrenergic receptor turnover (rat), 23, 282
 - Substance P
 - analogues, dissociation constants (guinea pig), 23, 558
 - binding to salivary membranes (rat), 23, 563
 - dissociation constant (guinea pig), 23, 558
 - in ileum (guinea pig), 23, 558
 - receptor
 - dissociation constants in ileum (guinea pig), 23, 558
 - in salivary membranes (rat), 23, 563
 - inactivation with phenoxybenzamine (guinea pig), 23, 558
 - Substrate
 - deoxycytidylate deaminase, chemotherapeutic implications (human), 23, 159
 - specificity (human), 23, 159
 - 4-hydroxylation of debrisoquine (human), 23, 474
 - thymidine kinase, 24, 316
 - Supersensitivity, acid amino acid receptors in hippocampus, 24, 229
 - Synapse, muscarinic cholinergic, 24, 1
 - Synaptic membrane, striatal
 - adenylate cyclase activity (rat), 23, 393
 - muscarinic receptors (rat), 24, 380
 - Synaptic vesicle
 - acetylcholine transport (ray), 24, 48
 - cholinergic (ray), 24, 48, 55
 - Synaptosomal vesicles, in brain (rat), 24, 251
 - Synergism, summation of inhibitory effects, 24, 30
 - Synthesis
 - DNA, inhibition, 23, 698
 - liver proteins, effect of halothane (rat), 24, 277
 - prostaglandin, effect of cannabinoids (human), 23, 121
- T
- Target size, neurotransmitter receptors (dog, human), 24, 10
 - Temperature
 - dependence
 - agonist binding, 24, 392
 - [³H]mepyramine binding, 23, 60
 - effect on dextromethorphan binding (guinea pig), 23, 619
 - effect on [³H]spiroperidol binding (rat), 23, 303
 - Testis, adenylate cyclase, effect of forskolin, 24, 42
 - Tetrabenazine, binding, chromaffin granules (bovine), 23, 431
 - 2,3,7,8-Tetrachlorodibenzo-*p*-dioxin, receptor in fibroblasts (mouse), 23, 198
 - Tetrahydrobiopterin
 - biosynthesis, 24, 103
 - folate antagonists, 24, 103
 - Tetrahydrofolate, hepatic, regulation (rat), 23, 724
 - Tetrahydropterin, cofactor in tyrosine hydroxylation (bovine), 23, 104
 - Tetrahydrotrazodone
 - binding sites, 23, 594
 - ³H-labeled, binding, 23, 594
 - Tetramethylammonium ion, electron distribution, 24, 443
 - Tetraphenylborate, effect on acetylcholine transport (ray), 24, 55
 - Thalamus
 - κ opiate agonists (rabbit), 24, 23
 - membranes (rabbit), 24, 23
 - Thioacetamide *S*-oxide, metabolism (rat), 23, 219
 - Thiol
 - methylation, 24, 471
 - nonprotein depletion (schistosoma), 24, 291
 - Thiopurine methyltransferase
 - action, 24, 471
 - effect of benzoic acid derivatives, 24, 471
 - Thymidine kinase
 - effects of 5'-amino-5'-deoxythymidine, 23, 709
 - herpes simplex virus, 24, 316
 - preferential inhibition, 24, 90
 - substrate specificity, 24, 316
 - Thymidylate kinase
 - effects of 5'-amino-5'-deoxythymidine, 23, 709
 - herpes simplex virus, 24, 316
 - Thyroid
 - hyperplasia
 - effect on enzymes (rat), 23, 641
 - propylthiouracil-stimulated (rat), 23, 641
 - hypertrophy
 - effect on enzymes (rat), 23, 641
 - propylthiouracil-stimulated (rat), 23, 641
 - metabolism, effect of hypophysectomy (rat), 23, 641
 - ornithine decarboxylase (rat), 23, 641

- Thyrotropin-releasing hormone, in GH₃ cells, effect on Ca²⁺ and cyclic AMP (rat), 23, 399
- Tiazofurin, *see* 2-β-D-Ribofuranosylthiazole-4-carboxamide
- Timolol, interaction with membranes, 24, 259
- Tolbutamide, oxidation (human), 23, 474
- Tolerance, ethanol, synaptosomal plasma membranes (mouse), 23, 86
- Torpedo californica*, electric organ, acetylcholine transport, 24, 48, 55
- Toxicity, *see also* Cytotoxicity, Hepatotoxicity
 cytological, α-1,3,5-triglycidyl-*s*-triazinetriene, 23, 182
 2'-deoxycoformycin, in spleen lymphocytes (mouse), 23, 165
 hepatic, cocaine (mouse), 23, 482
 nitrous oxide (rat), 24, 124
- Toxin
 cholera, effect on GTPase activity in striatal membranes (rat), 24, 380
 cobra α-, ¹²⁵I-labeled, 23, 8
- Trachea, smooth muscle (bovine), 23, 665
 α-adrenergic receptors (dog), 23, 570
 contraction (dog), 23, 570
 myosin phosphorylation, 24, 235
- Translation *in vitro*, messenger RNA (human), 23, 540; 24, 509
- Transport
 acetylcholine
 effect of tetraphenylborate (ray), 24, 55
 in synaptic vesicles (ray), 24, 48
 anion
 inhibition (ray), 24, 55
 inhibitors, 23, 92
 axonal, β-adrenergic receptors (rat), 24, 341
 6-azauridine, in lymphoblastoid cells (human), 23, 153
 Ca²⁺, in brain (rat), 24, 251
 electron, enhanced (rat), 24, 137
 membrane (human), 23, 146
 Na⁺, in brain (rat), 24, 251
 nucleoside (human), 23, 146
 heterogeneity in mammalian cells, 24, 479
 in lymphoblastoid cells (human), 23, 153
 mercuribenzenesulfonate inhibition, 24, 479
 pH-dependent, in lymphoblastoid cells (human), 23, 153
 uridine, in lymphoblastoid cells (human), 23, 153
- Tremorolytic agents, stereoselectivity (guinea pig), 23, 17
- Trifluoperazine, antagonism, α-adrenergic effects, 23, 67
- 5-Trifluoromethyl-2'-deoxyuridine, phosphorylation, preferential inhibition, 24, 90
- α-1,3,5-Triglycidyl-*s*-triazinetriene, antitumor and cytotoxic effects, 23, 182
- Triphenylmethylphosphonium, effect on binding and depolarization in cerebral cortex (guinea pig), 23, 350
- Tumor
 mammary, virus induction (mouse), 23, 779
 pituitary
 cellular Ca²⁺ metabolism (rat), 23, 399
 cellular cyclic AMP accumulation (rat), 23, 399
 -promoting phorbol esters, 23, 703
- Turnover, α-adrenergic receptor in submaxillary gland (rat), 23, 282
- Tyrosine hydroxylase
 dead-end and product inhibition (bovine), 23, 104
 steady-state kinetics (bovine), 23, 104

U

- Uptake, 3-*O*-methyl-D-glucose, in isolated hepatocytes (rat), 23, 141
- Uridine
 analogues
 transport in lymphoblastoid cells (human), 23, 153
 transport in lymphoblastoid cells (human), 23, 153

V

- Vas deferens
 α-adrenergic receptors (rat), 23, 359
 contraction (rat), 23, 359
 effects of apamine, methylene blue, and quinine (guinea pig), 23, 409
 effects of guanethidine (guinea pig), 23, 409
- Vasoactive intestinal peptide
 epithelial cell (rat), 23, 228
 modulation of adenylate cyclase in pituitary GH₃ cells, 24, 189
 modulation of cyclic AMP in pituitary GH₃ cells, 24, 189
 modulation of prolactin secretion in pituitary GH₃ cells, 23, 189
- Venom, scorpion, neurotoxins, 23, 519
- Ventricle, myocardial receptor for angiotensin II (rabbit), 24, 213
- Vesicle
 lipid, ionic permeability, 24, 270
 synaptosomal, in brain (rat), 24, 251
- Vinblastine, cellular accumulation (human), 24, 485
- Vinca alkaloid
 cellular accumulation (human), 24, 485
 retention, energy-dependent (human), 24, 485
- Virus, mammary tumor induction (mouse), 23, 779
- Voltage-sensitive channel, cerebral cortex (guinea pig), 23, 350

W

- Water, solubility of [³H]flunitrazepam binding sites (rat), 23, 310

X


- Xanthines, effect on coronary artery cells (bovine), 23, 424
- X-ray
 cell survival after exposure, 24, 84
 crystallography, conformation of neuroleptics, 24, 243
- Xylene, induction of cytochrome P-450 isozyme (rat), 23, 265

Y

- Yeast, growth inhibition, by aromatic heptaene macrolide antibiotics, 24, 270
- Yohimbine, ³H-labeled
 binding (rat), 23, 228
 identification of α₂-adrenergic receptor (rat), 23, 228

Z

- Zinc
 effect on monooxygenase activity (rat), 23, 467
 effect on NADPH oxidation (rat), 23, 467
 growth inhibition, 24, 77
 inhibition, in hepatic microsomes (rat), 23, 467
- Zinterol, binding in heart (human), 24, 169, 174

U.S. POSTAL SERVICE STATEMENT OF OWNERSHIP, MANAGEMENT AND CIRCULATION (Required by 39 U.S.C. 3685)									
1. TITLE OF PUBLICATION Molecular Pharmacology					A. PUBLICATION NO. 3 7 8 6 5 0 0 0			2. DATE OF FILING 10/1/83	
3. FREQUENCY OF ISSUE Bi-monthly					A. NO. OF ISSUES PUBLISHED ANNUALLY 6			B. ANNUAL SUBSCRIPTION PRICE Institutional: \$140.	
4. COMPLETE MAILING ADDRESS OF KNOWN OFFICE OF PUBLICATION (Street, City, County, State and ZIP Code) (Not printers) 9650 Rockville Pike, Bethesda, Maryland 20814									
5. COMPLETE MAILING ADDRESS OF THE HEADQUARTERS OR GENERAL BUSINESS OFFICES OF THE PUBLISHERS (Not printers) 9650 Rockville Pike, Bethesda, Maryland 20814									
6. FULL NAMES AND COMPLETE MAILING ADDRESS OF PUBLISHER, EDITOR, AND MANAGING EDITOR (This item MUST NOT be blank)									
PUBLISHER (Name and Complete Mailing Address) The American Society for Pharmacology and Experimental Therapeutics 9650 Rockville Pike Bethesda, Maryland 20814									
EDITOR (Name and Complete Mailing Address) Dr. Joel G. Hardman Vanderbilt University School of Medicine Department of Pharmacology Nashville, Tennessee 37232									
MANAGING EDITOR (Name and Complete Mailing Address) Kay A. Croker, Executive Officer 9650 Rockville Pike American Society for Pharmacology & Experimental Therapeutics Bethesda, Maryland 20814									
7. OWNER (If owned by a corporation, its name and address must be stated and also immediately thereunder the names and addresses of stockholders owning or holding 1 percent or more of total amount of stock. If not owned by a corporation, the names and addresses of the individual owners must be given. If owned by a partnership or other unincorporated firm, its name and address, as well as that of each individual must be given. If the publication is published by a nonprofit organization, its name and address must be stated.) (Item must be completed)									
FULL NAME					COMPLETE MAILING ADDRESS				
American Society for Pharmacology and Experimental Therapeutics					9650 Rockville Pike Bethesda, Maryland 20814				
8. KNOWN BONDHOLDERS, MORTGAGEES, AND OTHER SECURITY HOLDERS OWNING OR HOLDING 1 PERCENT OR MORE OF TOTAL AMOUNT OF BONDS, MORTGAGES OR OTHER SECURITIES (If there are none, so state)									
FULL NAME					COMPLETE MAILING ADDRESS				
9. FOR COMPLETION BY NONPROFIT ORGANIZATIONS AUTHORIZED TO MAIL AT SPECIAL RATES (Section 411.3, DMM only) The purpose, function, and nonprofit status of this organization and the exempt status for Federal income tax purposes (Check one)									
<input checked="" type="checkbox"/> (1) HAS NOT CHANGED DURING PRECEDING 12 MONTHS <input type="checkbox"/> (2) HAS CHANGED DURING PRECEDING 12 MONTHS (If changed, publisher must submit explanation of change with this statement.)									
10. EXTENT AND NATURE OF CIRCULATION					AVERAGE NO. COPIES EACH ISSUE DURING PRECEDING 12 MONTHS		ACTUAL NO. COPIES OF SINGLE ISSUE PUBLISHED NEAREST TO FILING DATE		
A. TOTAL NO. COPIES (Net Press Run)					2107		2100		
B. PAID CIRCULATION 1. SALES THROUGH DEALERS AND CARRIERS, STREET VENDORS AND COUNTER SALES					none		none		
2. MAIL SUBSCRIPTION					1521		1511		
C. TOTAL PAID CIRCULATION (Sum of 10B1 and 10B2)					1521		1511		
D. FREE DISTRIBUTION BY MAIL, CARRIER OR OTHER MEANS SAMPLES, COMPLIMENTARY, AND OTHER FREE COPIES					77		68		
E. TOTAL DISTRIBUTION (Sum of C and D)					1598		1579		
F. COPIES NOT DISTRIBUTED 1. OFFICE USE, LEFT OVER, UNACCOUNTED, SPOILED AFTER PRINTING					509		521		
2. RETURN FROM NEWS AGENTS					none		none		
G. TOTAL (Sum of E, F1 and 2 - should equal net press run shown in A)					2107		2100		
11. I certify that the statements made by me above are correct and complete					SIGNATURE AND TITLE OF EDITOR, PUBLISHER, BUSINESS MANAGER, OR OWNER  Executive Officer				

NOTICE

Molecular Pharmacology is no longer considering manuscripts for publication as “Short Communications.”



Notice to Authors Wishing to Submit Manuscripts to

Journal of Pharmacology and Experimental Therapeutics

Molecular Pharmacology

Drug Metabolism and Disposition

The expenses associated with the review of manuscripts submitted to those ASPET-sponsored journals that are devoted to publishing original research articles have escalated dramatically in recent years because of ever-increasing costs of postage, supplies, and other office expenses, and the growing number of manuscripts submitted for publication. In order to continue to offer authors the opportunity to publish their original research in our critically reviewed, well-edited, and widely respected journals, it has become necessary for ASPET to follow the example of several other scientific societies which have instituted a uniform manuscript handling fee for each of its journals that publishes original research reports. Therefore, all manuscripts received in the editorial office on or after July 1, 1983, must be accompanied either by a check for \$30.00 (in U. S. funds payable to ASPET) or by a validated purchase order from the authors' institution. The review process for submitted manuscripts will be delayed until the manuscript handling fee or purchase order is received in the appropriate Editor's office. We regret the necessity of instituting a manuscript handling fee. The Board of Publications Trustees has concluded, however, that this charge represents the fairest and most appropriate manner to defray the costs related to the review of submitted manuscripts. If submission of the manuscript handling fee entails a personal financial hardship to the author(s), the fee will be waived. In that event, the author(s) should submit a request for waiver of the fee when the manuscript is submitted.

INSTRUCTIONS TO AUTHORS

Molecular Pharmacology will publish the results of investigations that contribute significant new information on drug action or selective toxicity at the molecular level. The term "drug" is defined broadly to include chemicals that selectively modify biological function.

Suitable papers are those that describe applications of the methods of biochemistry, biophysics, genetics, and molecular biology to problems in pharmacology or toxicology. Also suitable are reports of fundamental investigations which, although not concerned directly with drugs, nevertheless provide an immediate basis for further study of the molecular mechanism of drug action. Observations of phenomena that shed no light upon underlying molecular interactions are not appropriate for publication. Comparative studies, such as those involving drug-receptor or drug-enzyme interactions that already have been well characterized in other types of cells or tissues, also are inappropriate for publication unless they contribute significant new insight into mechanisms.

Specific areas of interest include: stereochemical, electronic, and other parameters of drug architecture; conformational analysis of receptors and their function; drug-enzyme and other interactions between drugs and macromolecules; drug effects upon gene replication and transcription and on protein synthesis; mechanism of action of antibiotics and other growth-inhibitory drugs; induction by drugs of changes in macromolecular structure or allosteric transitions; drug-induced alterations in metabolic pathways; effects of hormones and other drugs on cellular regulatory mechanisms; chemical mutagenesis, carcinogenesis, and teratogenesis; pharmacogenetics, idiosyncrasies, and drug allergies; selective toxicity in a single organism or in different species; drug actions on properties and functions of membranes; mechanisms of drug metabolism; distribution and transport of drug molecules between biological compartments.

Page charges. Authors will be billed at the rate of \$30.00 per page after the paper has been published. It is expected that the page charge will be paid if funds are available for that purpose from the author's institution or from the sponsor of this research. Payment of the charge is not a condition for publication. In case of personal financial hardship, page charges will be waived. Neither the editors nor the reviewers will have knowledge as to who has paid the charge, and this payment always will be considered entirely voluntary.

Submission of manuscript. Manuscripts are published in English only and should be sent to Dr. Joel Hardman, Editor, *Molecular Pharmacology*, Department of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, U. S. A.

The expenses associated with the review of manuscripts submitted to *Molecular Pharmacology* and other ASPET-sponsored journals that are devoted to publishing original research articles have escalated dramatically in recent years because of ever-increasing costs of postage, supplies, and other office expenses, and the growing number of manuscripts submitted for publication. Thus, it has become necessary for ASPET to follow the example of several other scientific societies which have instituted uniform manuscript handling fees. Therefore, all manuscripts must be accompanied either by a check for \$30 (in U. S. funds payable to ASPET) or by a validated purchase order from the authors' institution. The review process for submitted manuscripts will be delayed until the manuscript handling fee or purchase order is received in the Editor's office. If submission of the manuscript handling fee entails a personal financial hardship to the author(s), the fee will be waived. In that event, the author(s) should submit a request for waiver of the fee when the manuscript is submitted.

Manuscripts should be typewritten double-spaced with ample margins on one side of the paper, 8½ × 11 inches (ca. 215 × 280 mm). Submit four complete copies of the manuscript and four copies of each figure, plus one original drawing or photograph of each figure. Each half-tone figure requires four original drawings or photographs. All pages should be numbered consecutively beginning with the title page. Limit your reference listings to the minimal number required to document the manuscript adequately. In most instances 30 references or fewer should suffice.

Under usual circumstances reviewers will be instructed to return only their comments to the editorial office and to destroy manuscripts after a final decision on their acceptability has been made.

Original figures and single copies of manuscripts not accepted for publication will be returned to the authors upon request.

It is understood that the manuscripts and the results they contain will not have been published previously and are not being submitted elsewhere. Manuscripts are accepted for review with the understanding that all persons listed as authors have given their approval for the submission of the paper; further, that any person cited as a source of personal communications has approved such citation. Written authorization may be required at the Editor's discretion. Articles and any other material published in *Molecular Pharmacology* represent the opinions of the author(s) and should not be construed to reflect the opinions of the Editor(s) and the Publisher. If and when a manuscript is published, it will become the sole property of the Journal.

Authors submitting a manuscript do so on the understanding that if it is accepted for publication, copyright in the article, including the right to reproduce the article in all forms and media, shall be assigned exclusively to the Society for Pharmacology and Experimental Therapeutics. No reasonable request by the author for permission to reproduce any of his or her contributions to the journal will be refused.

Organization and style of manuscripts. The policy of the Journal is to allow authors maximum freedom in organizing and presenting their material, and in expressing their ideas, provided only that clarity and conciseness are achieved. For most manuscripts, the most suitable format is: (1) Summary, (2) Introduction, (3) Materials and Methods, (4) Results, and (5) Discussion.

Certain conventions must be observed. Chemical and mathematical formulas and abbreviations should follow the *Instructions to Authors of the Journal of Biological Chemistry* (Vol. 258, pp. 1-11, January 10, 1983). Drugs must be referred to by their generic or chemical names throughout the text, but may be identified by trade name in parentheses or a footnote. The systematic name and number given by the Commission on Enzymes of the International Union of Biochemistry should be included for each enzyme of importance in a paper, at the point in the Summary or Introduction where the enzyme is first mentioned. The use of abbreviations should be minimized and abbreviations avoided in the Summary. All essential abbreviations should be defined in a single footnote when first introduced. Abbreviations of journal names should conform to the style of *Biological Abstracts*. References to papers that

have been accepted for publication, but have not appeared, should be cited like other references with the abbreviated name of the journal followed by the words "in press." Copies of such papers should be sent whenever the findings described in them have a direct bearing on the paper being submitted for publication. "Personal Communications" and "Unpublished Observations" should be cited in footnotes to the text and should not be included in the reference list.

A manuscript should include the following, in the order listed: (1) Title. Numbered footnotes to the title should be avoided; acknowledgment of financial support should be given in an unnumbered footnote to the title. (2) Names of authors, their laboratory and institution. (3) A running title, not exceeding 60 characters and spaces. (4) Summary. (5) Text. Footnotes should be referred to by superscript numbers and references by numbers in parentheses. (6) References, numbered according to order of citation in the text, including title and complete pagination. Examples: 1. Goren, J. H., L. G. Baue, and W. Vale. Forces and structural limitations of binding of thyrotropin-releasing receptor: the pyroglutamic acid moiety. *Mol. Pharmacol.* 13:606-614 (1977). 2. Sandler, M. Variations in monoamine oxidase activity in some human disease states, in *Monoamine Oxidase and Its Inhibition*. Ciba Foundation Symposium 39. Elsevier, Amsterdam, 327-340 (1976). (7). Footnotes, numbered according to order of appearance in the text. (8) Tables. (9) Figures. (10) Legends to figures. (11) Name and address of person to receive galley proof.

Tables. These should be numbered with arabic numerals and designed to fit the single-column width of the full-page width. Every table should have an explanatory title and sufficient experimental detail in a paragraph following the title to be intelligible without references to the text (unless the procedure is given in the Methods

section, or under another table or figure). Footnotes to tables should appear beneath the tables themselves and should be designated by lower-case italic superscript letters, *a*, *b*, *c*, etc.

Figures. These should be numbered with arabic numerals. Each of the four manuscript copies should contain all of the figures. Only the original set need be of quality suitable for reproduction except in the case of half-tones, which require four sets of photographs or original drawings. These should be unmounted glossy photographs (or original India-ink drawings). Usually figures will be reduced to one column width (85 mm) and all numbers *after* such reduction should be at least 1.5 mm high. The figures must be ready, in all respects, for direct reproduction: no lettering or other art work will be done by the publisher. If symbols are not explained on the face of the figure, only standard characters, of which the printer has type, may be used (\times , \circ , \bullet , \square , \blacksquare , \triangle , \blacktriangle , \odot). The back of each photograph should bear its number, and the legend TOP at the appropriate edge. The list of legends for the figures should give captions and sufficient experimental detail, as required for tables.

Galley proof. The cost of all changes on galley proof, other than printer's errors, will be charged to authors. The Editors are very much interested in having accepted contributions appear in the earliest possible issue of the Journal, and therefore request that galley proof be returned within 24 hours after its receipt. In exceptional cases, a "Note added in proof" may be attached and will be published if the Editor approves.

Reprints and page charges. An order form for reprints as well as information on the estimation of page charges will be mailed with galley proof. Please direct questions on reprints, page charges, or other business matters to Kay Croker, Executive Officer, American Society for Pharmacology and Experimental Therapeutics, 9650 Rockville Pike, Bethesda, Md. 20814. Telephone (301)530-7060.